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ABSTRACT 
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous 
system in which oligodendrocytes and myelin are targeted and destroyed by the body’s immune 
system. Chemical elements such as iron, sulfur, and phosphorous are crucial in the synthesis and 
maintenance of myelin, and their imbalances have been linked to demyelination and 
neurodegeneration.  
Early MS is heterogeneous with respect to its neuropathological features suggesting that 
the target of injury and the mechanisms of demyelination are different in different patient 
subgroups, also called immunopatterns. Using a multidisciplinary approach that combines 
synchrotron X-ray fluorescence imaging (XFI), histology and immunohistochemistry, I firstly 
investigated the heterogeneity of iron content and distribution in immunopattern II and III MS, to 
determine whether iron can be used as a marker to differentiate immunopatterns. XFI showed that 
iron was significantly increased in immunopattern II lesions (p=0.003) and predominantly stored 
as ferritin within myelin-laden macrophages. These observations prove that there is a profound 
iron heterogeneity in early active MS lesions and I propose that iron dysregulation plays an 
important role in the pathogenesis of MS lesions. My findings have potentially important clinical 
implications because iron may be used as a magnetic resonance imaging biomarker, allowing 
routine early immunopattern recognition in the clinical setting and advancing treatment approaches 
specific to the pathology.  
The human brain is highly susceptible to oxidative damage due to its high concentrations 
of lipids and unsaturated fatty acids. Iron has been proposed to promote MS tissue injury through 
generation of toxic reactive oxygen species which damage carbohydrates, lipids, proteins, and 
DNA. Using XFI and Fourier-transform infrared imaging, I found that biopsied early MS lesions 
displayed increased oxidized lipids and aggregated proteins, and lower iron, sulfur, phosphorus 
and phosphate. The oxidative damage in early MS does is not driven by iron accumulation, and 
this argues against the use of iron chelators in the treatment of early MS.  
Future studies will have to determine if the differential iron distribution between 
immunopatterns II and III MS is the result of different macrophage polarization in the two lesion 
patterns and/or is the expression of the iron’s role in complement cleavage and activation 
characteristic of immunopattern II MS lesions. 
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Chapter 1 General Introduction 
1.1 Multiple Sclerosis  
An estimated 100,000 Canadians are living with multiple sclerosis (MS), which is a 
disabling disease with mean onset age in early adulthood and a female-male ratio of approximately 
3:1 (Bove & Chitnis, 2014; Ransohoff, Hafler, & Lucchinetti, 2015). A population-based 
prospective study of Saskatoon, Saskatchewan MS patients found that about 27% of the patients 
were born in the city of Saskatoon, indicating a high local prevalence (Hader & Yee, 2007). MS 
prevalence varies worldwide with countries like Canada, which have large populations originating 
from Northern Europe, having more than 100-200 cases per 100,000 people (Milo & Kahana, 
2010). This prevalence variability may be relevant to the etiology and pathology of MS. MS is an 
inflammatory, demyelinating disease of the central nervous system (CNS) with a poorly defined 
and complex pathogenesis (Ingram, Hakobyan, Robertson, & Morgan, 2009).  
Much progress has been made in MS research over the years; however, there is no 
prevention or cure, and treatment responses remain largely unpredictable. By describing MS as a 
disease with demyelinating lesions in the CNS, a wide variety of disorders can become compiled 
under one umbrella term. By that description, past research sought a single cause of MS and thus, 
a single therapy that would work for all MS patients. However, this focus does not take into 
account the clinical, genetic, and radiographic heterogeneity that affects the variability of patient 
responses to any given therapy (Popescu & Lucchinetti, 2012b). Currently, researchers are moving 
away from the single therapy approach because there is a large body of evidence strongly 
suggesting that MS results from complex interactions between genetics and environmental factors 
(Milo & Kahana, 2010).  
A longitudinal study reported that multiple active lesions within the same individual have 
the same pattern (Lucchinetti et al., 2000). The authors studied tissues serially collected at either 
two different biopsies or at biopsy and then at autopsy, and found that the pattern of lesions from 
the same patient remained consistent over the time points. They also showed that other active 
lesions at different sites exhibited the same pattern within the same patient (Metz et al., 2014). 
This suggests that the targets of injury and mechanisms of demyelination in early MS might be 
fundamentally different in MS patient subgroups (Bitsch & Bruck, 2002; Lucchinetti et al., 2000). 
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1.2 Pathology of Multiple Sclerosis 
Although no target antigen has been identified as proof for MS as an autoimmune disease, 
it is generally believed that tissue damage is driven by an “inflammatory process of a putative 
autoimmune nature” (Lassmann, Bruck, & Lucchinetti, 2007). The neuropathological hallmark of 
MS is a demyelinated lesion encompassing various levels of inflammation, gliosis, demyelination, 
and axonal damage (Filippi et al., 2012). Lesions form in the grey matter (Popescu & Lucchinetti, 
2012a) and white matter of the brain (Lassmann, 2014a).  
In the brain, the gray matter forms the outer covering called cortex and also forms clusters 
deep within the white matter of the forebrain and cerebellum called nuclei. Gray matter contains 
cell bodies, dendrites, and axons of neurons, as well as glial cells (Martini, Timmons, & Tallitsch, 
2015). Cortical lesions and atrophy are thought to be the earliest pathological event in the MS 
disease course and in some MS cases, preceding the formation of white matter lesions (Calabrese 
& Gallo, 2009; Popescu & Lucchinetti, 2012a). Neuronal loss and apoptosis, loss of dendrites, and 
transected axons have been reported in cortical MS lesions (Peterson, Bo, Mork, Chang, & Trapp, 
2001; Wegner, Esiri, Chance, Palace, & Matthews, 2006). Neurons are important functional units 
of the nervous system and consist of a cell body containing a large, round nucleus and a distinctive 
nucleolus. Dendrites extend from the cell body and receive information from other neurons, while 
axons transmit impulses away from the cell body to the synaptic terminals where the neuron 
communicates with another neuron or an effector organ (Martini et al., 2015; Ross & Pawlina, 
2011). Damage to these structures impairs information processing in the cortex and may contribute 
to cognitive defects observed in MS patients (Popescu & Lucchinetti, 2012a).  
White matter in the brain contains only myelinated neuronal axons and their associated 
glial cells and blood vessels (Blumenfeld, 2010; Gartner & Hiatt, 2007; Ross & Pawlina, 2011). 
Glial cells in the CNS include microglia, astrocytes, ependymal cells, and oligodendrocytes. 
Normally, microglia are immunocompetent cells that are constantly scanning the 
microenvironment for foreign invaders and are the first line of defense against tissue injury or 
pathogens. They are known as the “CNS professional macrophages” and serve as housekeepers of 
the microenvironment, cleaning up accumulated metabolic products and cellular debris (Farina, 
Aloisi, & Meinl, 2007; Katsumoto, Lu, Miranda, & Ransohoff, 2014; Mildner et al., 2007; Prinz 
& Mildner, 2011). Their various functions include phagocytosis and antigen presentation; but 
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under intense acute activation or chronic activation, microglia become neurotoxic (London, 
Cohen, & Schwartz, 2013). They produce cytokines, complement components, excitatory 
neurotransmitters (glutamate), and free radicals (Cross & Piccio, 2014; London et al., 2013) that 
can participate in the evolution of MS lesions.  
Astrocytes are star-shaped glia and are the most abundant cells in the CNS. They provide 
physical and metabolic support for neurons and help maintain the tight junctions of the capillaries 
that form the blood-brain barrier (BBB) (Gartner & Hiatt, 2007). Astrocytes have been implicated 
as modulators of myelination through secretion of factors that affect oligodendrocyte 
differentiation (S. C. Barnett & Linington, 2013). Current research also suggests that activated 
astrocytes may have neuroprotective roles via the innate immune system in lesioned areas. 
Reactive astrocytes outline the area of damage and control leukocyte migration across the BBB, 
repair the BBB, and support neuron survival, after a CNS insult (Farina et al., 2007). 
Ependymal cells are cuboidal to columnar in shape and are organized in a single epithelial-
like layer lining the ventricles of the brain and the central canal of the spinal cord. These cells have 
processes that extend into the brain parenchyma and directly communicate with other glial cells. 
Ependymal cells may be involved in monitoring the composition and circulation of cerebrospinal 
fluid (CSF). Modified ependymal cells join with the pia mater to form the choroid plexus, which 
is responsible for producing CSF (Gartner & Hiatt, 2007; Martini et al., 2015). Analysis of CSF 
for the presence of immunoglobulin G (IgG) oligoclonal bands, which are immunoglobulins 
specific to CSF, may be used as support towards a diagnosis of MS (Link & Huang, 2006). 
However, CSF is not commonly used anymore and is no longer a part of the diagnostic criteria for 
relapsing-remitting MS (Polman et al., 2011).  
Oligodendrocytes are the glial cells in the CNS that produce and maintain myelin that 
encases axons. Myelin is integral for transmission of messages along the axon. Myelin is 70-80% 
lipid, and also contains protein and water. The major lipid components are cholesterol, 
phospholipids, and glycosphingolipids (Mancall & Brock, 2011). In MS, myelin and 
oligodendrocytes are targeted and destroyed by the body’s immune cells resulting in large 
confluent demyelinated lesions. 
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1.2.1 Demyelination 
Demyelinated MS lesions contain numerous macrophages. These may be monocyte-
derived macrophages recruited from the circulation to help in place of microglia that have become 
neurotoxic and can no longer carry out protective functions in the damaged tissue (London et al., 
2013). Early studies showed that macrophages were heterogeneous and could be used to 
differentiate demyelinating activity (Bruck et al., 1996). One diagnostic approach in pathologically 
classifying MS lesions is based on the presence and distribution of myelin-laden macrophages 
within the lesion (Popescu & Lucchinetti, 2012b). Lesions can be classified into five types: active, 
chronic active, smoldering demyelinated, inactive, or remyelinated (Popescu & Lucchinetti, 
2012b).  
1.2.1.1 Types of Demyelinated Lesions 
Active lesions are demyelinated lesions infiltrated by macrophages containing cytoplasmic 
myelin debris. Reactive astrocytes and inflammatory infiltrates comprised mainly of T 
lymphocytes, some B lymphocytes, plasma cells, and granulocytes, are also present in these 
lesions. Oligodendrocytes are variably lost and there is some axonal injury indicated by axonal 
swellings and buildup of β-amyloid precursor protein. There is also extensive BBB damage that 
may lead to the invasion of the CNS by inflammatory cells (Popescu, Pirko, & Lucchinetti, 2013). 
Gadolinium enhancement on MRI shows BBB damage and suggests the presence of inflammation 
(Haacke et al., 2009). 
Chronic active lesions are present more often in the progressive phases of MS. 
Macrophages accumulate at the lesion edge with few at the inactive centre and these lesions show 
astrogliosis and significant loss of oligodendrocyte axons. Inflammatory infiltrates are typically 
located perivascularly with an either an intact BBB or the BBB damage is too minimal to be 
detected by gadolinium enhancement (Popescu et al., 2013).  
Smouldering lesions, also known as slowly expanding lesions, are typically seen only in 
the progressive phase. These are demyelinated lesions with a distinct rim of macrophages and 
microglia, but only a few contain myelin debris.  
Inactive lesions are completely demyelinated and have either an absence of macrophages 
or few macrophages that do not contain myelin debris, a few microglia and a glial scar. 
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Inflammatory cells consisting of macrophages and microglia, lymphocytes, and plasma cells are 
also present.  
Remyelinated lesions are sharply demarcated and have thinly myelinated axons and 
oligodendrocyte precursor cells (OPCs). The presence of the latter as well as the balance between 
pro- and anti-inflammatory environments determine the extent of remyelination (Patrikios et al., 
2006; Popescu et al., 2013). Early stage remyelination is extensive, contains a lot of newly formed 
myelin sheaths and OPCs, and is often seen in active lesions of the early phase of MS. Shadow 
lesions are sharply demarcated and completely remyelinated lesions typical of late stage 
remyelination. Some shadow lesions contain nearly normal myelin thickness that is hard to 
differentiate from normal white matter (Popescu et al., 2013). Shadow lesions also show decreased 
axonal density, few inflammatory infiltrates surrounding blood vessels but do not contain myelin-
laden macrophages (Patrikios et al., 2006).  
1.2.1.2 Patterns of Demyelination 
On the basis of the specific myelin degradation proteins present within macrophages, active 
lesions can be classified into early or late stages of demyelination. Macrophages containing minor 
myelin degradation products, such as myelin-associated glycoprotein (MAG) and myelin 
oligodendrocyte glycoprotein (MOG), indicate an early active lesion. Macrophages containing 
major myelin proteins, such as proteolipid protein (PLP) or myelin basic protein (MBP), are 
digested more slowly and indicate a late active lesion (Popescu et al., 2013). By identifying the 
stage of demyelination, early active white matter lesions can further be segregated into patterns of 
demyelination. A detailed and systematic neuropathological study performed on a large collection 
of early active MS lesions from biopsy and autopsy material found a significant heterogeneity of 
lesions and identified four patterns of demyelination with possible distinct disease mechanisms 
(Bitsch & Bruck, 2002; Lucchinetti et al., 2000). Only early active lesions were classified into 
patterns based on specific myelin protein loss; lesion characteristics and location; oligodendrocyte 
destruction; and immunoglobulin (Ig) deposition and complement activation (Lucchinetti et al., 
2000). Early active lesions are required for pattern classification because it implies that the disease 
is active and they also represent early stages of lesion development (Metz et al., 2014). 
Demyelination in immunopatterns I and II is primarily immune-mediated and is propelled 
by activated macrophages that destroy and phagocytose myelin. Demyelination in these two 
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patterns occurs on a background of inflammation. Immunopattern I occurs in approximately 15% 
of biopsied patients and is a T-cell/macrophage-mediated demyelination. Lesions are sharply 
demarcated, situated perivascularly and lack immunoglobulin deposition and complement 
activation.  
Immunopattern II lesions are found in about 58% of biopsied patients and are also T 
cell/macrophage-mediated demyelination; however, the major feature found exclusively in 
immunopattern II is the prominent deposition of immunoglobulins and complement C9 neoantigen 
at sites of active myelin destruction and association with myelin degradation products within 
macrophages. This is suggestive of cellular and humoral mediated autoimmunity. Immunopatterns 
I and II frequently exhibit remyelinated lesions with loss of oligodendrocytes at actively 
demyelinating sites and appearance of OPCs in the inactive region (Lucchinetti et al., 2000; 
Popescu et al., 2013).  
Immunopatterns III and IV lesions have been primarily associated with 
oligodendrogliopathy (Lucchinetti et al., 2000). Immunopattern III is found in 26% of biopsied 
patients and the lesions are not well defined with active demyelination and oligodendrocyte 
apoptosis. Oligodendrocyte loss extends into the normal-appearing white matter and there is an 
absence of oligodendrocytes at the inactive centre. Remyelinated lesions are not observed. A 
striking feature of immunopattern III demyelinated lesions is the preferential loss of MAG in 
comparison to other myelin proteins, such as PLP or MOG. MAG is located in the periaxonal layer 
of myelin on the distal processes of oligodendrocytes. The loss of MAG is associated with a “dying 
back oligodendrogliopathy”, and oligodendrocyte death by apoptosis. “Dying-back 
oligodendrogliosis” is indicative of metabolically stressed oligodendrocytes that are no longer able 
to support their distal processes (Lucchinetti et al., 2000; Popescu & Lucchinetti, 2012b). 
Interestingly, preferential loss of MAG has also been observed in acute white matter ischemia 
(Aboul-Enein et al., 2003). This suggests that hypoxia-like injury, potentially via mitochondrial 
dysfunction, may be involved in the pathogenesis of immunopattern III lesions (Mahad, Ziabreva, 
Lassmann, & Turnbull, 2008).  
Immunopattern IV lesions are rare and are found in approximately 1% of autopsy tissues 
from patients with progressive MS. They feature significant non-apoptotic oligodendrocyte death 
in the white matter surrounding the active lesion. (Lucchinetti et al., 2000; Popescu & Lucchinetti, 
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2012b). It is possible that the oligodendrocytes have some genetic defect that makes them more 
susceptible to the effect of inflammatory processes (Lassmann, 2014a; Popescu et al., 2013).  
1.2.2 Inflammation  
Gadolinium enhancement in MRI can identify BBB damage that leads to infiltration of 
inflammatory cells into the CNS (Filippi et al., 2012; Popescu et al., 2013). Inflammatory 
infiltrates are present at every stage of the disease and may even be present without ongoing active 
demyelination (Lassmann, 2014b; Lucchinetti, 2011). However, it has been noted that anti-
inflammatory, immunomodulatory or immunosuppressive therapies are relatively effective in the 
early disease phase, but appear less effective in the progressive phase. This suggests that 
inflammation may play a significant role in tissue injury in the early stage of disease, whereas, 
neurodegenerative processes may drive the progressive stage (Lassmann, 2014a; Lassmann et al., 
2007).  
The inflammatory infiltrates in MS demyelinating lesions are primarily composed of CD8-
positive cytotoxic T lymphocytes, and phagocytic macrophages derived from either monocytes or 
microglia (Bruck et al., 1995; Mahad, Trapp, & Ransohoff, 2005). CD8+ T lymphocytes 
specifically recognize only antigens on Major Histocompatibility Complex (MHC) class I 
molecules and secrete lymphokines and perforins resulting in pathogen lysis (Ross & Pawlina, 
2011). MHC I antigens are highly expressed in MS lesions on inflammatory cells, neurons, and 
glia (Lassmann et al., 2007). Monocytes are blood mononuclear cells that travel from bone marrow 
to differentiate into phagocytic cells of the mononuclear phagocytic system (Ross & Pawlina, 
2011). With inflammation, all of the microglia and monocyte-derived cells can become tissue 
macrophages and these cells are involved in the immune processes underlying demyelination, such 
as myelin degradation, antigen presentation, lipid peroxidation, and production of cytokines 
(Bruck et al., 1995; Katsumoto et al., 2014). Components of destroyed myelin are targeted by 
macrophages and after internalization, the progression of degradation of specific myelin proteins 
occurs at different rates (Popescu & Lucchinetti, 2012b).  
1.2.3 Oxidative Injury  
Oxidative stress is suggested to play a critical role in the early, active stage of MS with 
contributions to neurodegeneration at later stages (Carvalho, Lim, Nijland, Witte, & Van Horssen, 
2014). Oxidized deoxyribonucleic acid (DNA) and oxidized lipids are present within MS active 
8 
 
lesions and mainly accumulate in oligodendrocytes and myelin, which is associated with 
continuing demyelination. Oligodendrocytes make a lot of adenosine triphosphate (ATP) in order 
to support myelin membranes and have been shown to be more susceptible to oxidative stress than 
astrocytes and microglia in vitro (Mahad et al., 2008; Todorich, Pasquini, Garcia, Paez, & Connor, 
2009).  
Two main sources are responsible for creating reactive oxygen species (ROS): 
mitochondrial dysfunction and activated microglia and macrophages through oxidative burst 
(Carvalho et al., 2014). ROS are small oxygen-derived molecules that are oxidizing agents or can 
be converted to oxygen radicals (Bedard & Krause, 2007). ROS-producing enzymes such as 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOXs) and inducible nitric 
oxide (iNOS) are highly expressed in macrophages and microglia to kill pathogens through a 
process called oxidative burst (Bedard & Krause, 2007; Carvalho et al., 2014). Macrophages and 
microglia have been identified as a major source of ROS in initial MS lesions compared with 
control white matter, with increased expression of NADPH oxidase-I (Nox1) and Nox2. This 
suggests that initial oxidative damage is driven by the inflammation-induced oxidative burst in 
activated macrophages and microglia. Oxidative damage then results in mitochondrial respiratory 
chain dysfunction, further propagating oxidative injury and ROS production (Fischer et al., 2012).  
There are extensive mitochondrial disturbances in active immunopattern III MS lesions 
that result in energy deficiency (Lassmann, 2014a). The mitochondrial respiratory chain has four 
complexes, I-IV, and ATP synthase. The final respiratory chain complex, complex IV or 
cytochrome c oxidase [COX], is where 90% of oxygen is consumed and where proton pumping 
for ATP synthesis occurs (Mahad et al., 2008). Levels of subunit-I of complex IV (COX-I) and 
subunit-IV (COX-IV) are reduced in pattern III early active and late active lesions. Thus, 
mitochondrial defects lead to impairment of activity, assembly, and stability of complex IV 
(Mahad et al., 2008).  
Mitochondrial injury and resulting energy disruptions have been shown to be a major 
driving factor of MS tissue injury (Haider et al., 2011). Normally, mitochondria produce ROS for 
signalling functions as a by-product of cellular respiration. However, when ROS production 
exceeds the cellular antioxidant capability, they can become critical mediators of oxidative stress 
resulting in damage to important cellular components such as lipids, proteins and DNA in early 
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and chronic stages of MS (Carvalho et al., 2014; Haider et al., 2011; van Horssen et al., 2008; 
Witte, Mahad, Lassmann, & van Horssen, 2014).  
1.3 Elemental Distribution in MS 
1.3.1 Iron Distribution 
Metals play an important role in the CNS and are vital to essential functions such as energy 
production, nerve transmission, and oxygen transport. Iron (Fe) is an essential trace metal that 
plays a crucial role in physiological brain metabolism, oxygen transport, myelin synthesis, 
neurotransmitter production, and oxidative stress (Ropele et al., 2011). Iron is needed for oxidative 
metabolism and the brain has a high rate of oxidative metabolism most likely associated with the 
oligodendrocyte maintaining a myelin sheath that is 100 times its weight (Connor & Menzies, 
1996). Myelin production and maintenance in the CNS depend on oligodendrocytes, the cells that 
stain for iron more robustly than any other cell in the adult brain, under normal conditions 
(Todorich et al., 2009). Numerous enzymes involved in cholesterol and lipid synthesis, which are 
both vital components of myelin and ATP production, require iron as a cofactor (Todorich et al., 
2009).  
Biologically, iron can be divided into heme iron and nonheme iron according to chemical 
structure and metabolism. Heme is a prosthetic group involved in oxygen transport, electron 
transport and oxidation-reduction reactions.  Nonheme iron exists in a ferrous (Fe2+) or ferric (Fe3+) 
oxidation state and ferric iron is predominant in human brain (Schenck, 2010). Most of the iron in 
the human brain is stored as nonheme iron in oligodendrocytes and myelin (Hametner et al., 2013). 
Iron is a “redox active” metal because it can redox cycle between its ferrous and ferric oxidation 
states to catalyze oxidation-reduction reactions (Meguro et al., 2007; Schenck, 2010). Nonheme 
iron is involved in the production of cytotoxic hydroxyl radicals (OH·) through the Fenton reaction 
and the Haber-Weiss reaction (Crichton, 2009). OH· are highly reactive and have the ability to 
oxidize lipids, proteins, carbohydrates, and DNA (van Horssen et al., 2008). It has also been 
suggested that iron is liberated from destruction of myelin and this results in amplification of 
oxidative injury in MS lesions (Haider, 2015; Hametner et al., 2013). Iron levels must be regulated 
to avoid iron toxicity stemming from excess iron or iron deficiency (Ye & Rouault, 2010). The 
cell keeps iron either in the iron-transport system as transferrin or in the iron-storage system as 
ferritin and hemosiderin (Meguro et al., 2007).  
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Transferrin is an important protein that carries iron into the brain across the BBB. Iron 
accumulation is important during early brain development and iron is released from transferrin by 
microglia and delivered to OPCs (Todorich et al., 2009). However, as oligodendrocytes develop, 
there is a down-regulation of transferrin receptors and mature oligodendrocytes do not express 
transferrin receptors, even in hypomyelination conditions, yet oligodendrocytes still acquire iron 
(Leitner & Connor, 2012; Todorich et al., 2009).  
The major iron delivery system to mature oligodendrocytes was shown to be ferritin. 
(Todorich, Zhang, & Connor, 2011). Ferritin is a ubiquitous and highly conserved protein that 
plays a major role in iron homeostasis by sequestering and storing iron in a non-toxic, redox-
inactive, and soluble form. It is capable of storing up to 4,500 iron atoms in the form of ferrihydrite. 
Mammalian ferritins have variable amounts of heavy (H) and light (L) -chain ferritins (Zecca, 
Youdim, Riederer, Connor, & Crichton, 2004). The H subunits confers ferroxidase activity that 
catalyzes the aerobic oxidation of Fe2+ to Fe3+ and the L subunits have no enzymatic activity but 
is responsible for transferring the Fe3+ to the iron core. Most of the iron in the human brain is 
ferritin-bound and the primary function of ferritin is the storage of iron. This keeps the iron in a 
safe form where Fe3+ is not freely available for conversion to the toxic ferrous form used in 
oxidative reactions (Asano et al., 2015; Friedman, Arosio, Finazzi, Koziorowski, & Galazka-
Friedman, 2011; Meguro et al., 2007). H-ferritin is the main iron delivery system to 
oligodendrocytes because it prevents loss of cell viability after transferrin deprivation, and 
microglia were shown to provide iron to oligodendrocytes via H-ferritin (Todorich et al., 2011). 
Oligodendrocytes have the reported ability to upregulate ferritin expression and synthesis during 
hypoxia, leading to iron sequestration, which is thought to be a protective mechanism against 
oxidative injury (Qi & Dawson, 1994).  
A study looking at transferrin and H-ferritin binding in the normal human brain found that 
there was a non-overlapping pattern of distribution of the two iron storage proteins, with transferrin 
found primarily in grey matter and ferritin in white matter. This non-overlapping pattern was also 
observed in MS lesions and it was concluded that the presence of transferrin indicated the presence 
of immature oligodendrocytes and ferritin was associated with mature oligodendrocytes (Hulet, 
Powers, & Connor, 1999). 
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Iron dyshomeostasis and pathological deposition of iron have been associated with 
numerous MS disease processes such as continuing demyelination, remyelination, axonal damage, 
and neurodegeneration (LeVine, Bilgen, & Lynch, 2013; Stephenson, Nathoo, Mahjoub, Dunn, & 
Yong, 2014), MRI and histopathological studies have suggested that iron levels may have an effect 
on pathological mechanisms underlying MS and could be used to study heterogeneity of MS 
lesions (Bagnato et al., 2011; Yao et al., 2015). A study reported that ferritin levels in the CSF of 
chronic progressive active MS patients were higher than normal, while the levels of transferrin and 
iron did not significantly increase. The authors suggested that an elevated ferritin level was a 
defense mechanism against inflammatory processes occurring in the CNS, such as increased 
cytokine levels (LeVine et al., 1999). A later study showed that H-ferritin expression in 
oligodendrocyte precursors increased in response to higher iron levels and the presence of 
cytokines did not affect this increase (Zhang et al., 2005). The authors also mentioned that 
oligodendrocytes were more susceptible to toxicity from certain cytokines, such as TNF-α and 
IFN-γ, after iron loading. It was suggested that increased mitochondrial iron levels from the iron 
loading resulted in mitochondrial dysfunction and subsequent vulnerability of oligodendrocytes to 
TNF-α, IFN-γ, and oxidative injury (Zhang et al., 2005).  
A study probed the elemental makeup of serum from MS patients and found that serum 
iron levels could be used to differentiate between patients with clinically definite MS and healthy 
donors. Patients with clinically definite MS had lower serum iron and higher serum oxidative status 
than healthy donors (Ristori et al., 2011). Oligodendrocytes and myelin also store iron accumulated 
in the human brain with age; thus, their destruction in the MS disease process may release this iron 
that can amplify harmful oxidative processes (Lassmann, 2014b). However, it is also possible that 
iron deficiency, which has been implicated in restless legs syndrome, drives pathology in MS 
(Connor et al., 2011). The existence of abnormal iron deposits and their exact role in MS remains 
to be elucidated. 
1.3.2 Sulphur Distribution 
Sulphur may also play a role in the pathogenesis of MS lesions. Iron is imported into 
mitochondria where it is used to synthesize iron-sulphur (Fe-S) clusters and serves as a cofactor 
for cytochromes a, b, and c. Fe-S clusters are involved in cell functions such as respiration, 
catalysis, and redox reactions (Todorich et al., 2009; Ye & Rouault, 2010). Fe−S proteins have 
12 
 
prosthetic groups comprising two or more iron atoms bridged by sulphur ligands, which facilitate 
multiple functions such as redox activity and enzymatic function (Ye & Rouault, 2010). 
Dysfunction of Fe–S cluster protein formation results in mitochondrial iron overload and cytosolic 
iron depletion in mammalian cells (Rouault, 2012). Damage to Fe-S clusters releases iron, which 
can then participate in the Fenton reaction to create ROS (Slauch, 2011). 
Sulphur-containing amino acids are more abundant in animal proteins and sulphur is an 
integral part of numerous enzymes and antioxidant molecules, such as glutathione (Mukwevho, 
Ferreira, & Ayeleso, 2014). Glutathione is highly sensitive to cellular redox changes and indicates 
cellular oxidative stress, which could lead to its use as a biomarker in MS (Carvalho et al., 2014). 
Cysteine and methionine residues are very sensitive to oxidation by almost all ROS (Berlett & 
Stadtman, 1997). Methionine and cysteine residues are also vulnerable to oxidation by 
peroxynitrite (Berlett & Stadtman, 1997). Peroxynitrite is formed in a reaction between nitric oxide 
and superoxide and once formed, it can convert tyrosine residues into nitrotyrosine (van Horssen 
et al., 2008). Nitrotyrosine has been found to localize within myelin-laden macrophages and 
reactive astrocytes in active MS lesions and is a marker of oxidative damage (van Horssen et al., 
2008). Elemental sulphur is a component of sulfatides, which combines with cerebrosides to form 
galactolipids, which are abundant constituents of myelin (Stuber et al., 2014).  
1.3.3 Phosphorous Distribution 
Myelin is made of 70% lipid and the specific lipids include cholesterol, galactolipids, and 
phospholipids (Stuber et al., 2014). Phosphorous is also found in the helical strands of DNA in 
phosphomonoester and phosphodiester proteins; and in phosphocreatine and nucleoside 
phosphates like ATP and adenosine diphosphate (ADP), which are important for energy storage 
and transfer. A significant amount of phosphorous is found in phospholipids, accounting for 
approximately 80% of all phosphorous in white matter and 60% in gray matter. This means that 
phosphorous can be used as a marker of myelin distribution (Stuber et al., 2014).   
A study designed to analyze the presence and location of oxidized DNA and lipids in MS 
showed that oxidized DNA was found in areas with significant microglial activation at the lesion 
edge, apoptotic oligodendrocytes, and astrocytes. They also found oxidized phospholipids in 
oligodendrocytes and myelin, and degenerating axons and neurons, in active MS lesions (Haider 
et al., 2011). Lipid peroxidation occurs when ROS are produced close to lipid-rich cell membranes 
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and the resulting reactive aldehyde species diffuse throughout the cell and covalently modifies 
DNA, lipids, and proteins (Fritz & Petersen, 2011). 
1.4 Elemental Mapping Using Synchrotron Light 
1.4.1 Synchrotron Radiation 
Synchrotron radiation is electromagnetic radiation emitted by electrons moving at 
relativistic speeds following a curved trajectory (Kim, 2009). The source of electrons is a tungsten-
oxide disk located in an electron gun. High voltage electricity passes through this disk and heats it 
to about 1000°C, which allows electrons to escape the surface. There is a powerful positive charge 
that repels the released electrons in to the linear accelerator. The linear accelerator contains a series 
of radio frequency cavities, which are special cavities that transfer energy to passing electrons. 
From the linear accelerator, electrons enter the booster ring for another energy increase and then 
they travel at approximately the speed of light. These electrons are then injected into straight 
sections of the storage ring. Bend magnets inside the storage ring change the direction of the 
circulating electrons so they emit synchrotron radiation. Special magnets called insertion devices 
move the electrons back and forth in order to create higher flux photons, or more intense light, for 
the beamline. This synchrotron radiation then travels through a photon port towards experimental 
beamlines.  
Each beamline consists of an optics hutch, experimental hutch, and work station. In the 
optics hutch, light is focused and a monochromator is used to separate different wavelengths. Once 
the relevant wavelengths are selected, mirrors focus the beam on to the sample in the experimental 
hutch and a detector picks up the data and sends it to the work station to be analyzed (Canadian 
Light Source, 2012). A microfocused X-ray beam excites specific elements within a sample to 
release X-ray fluorescence and numerous chemical elements can be investigated simultaneously 
(Pushie, Pickering, Korbas, Hackett, & George, 2014). 
Synchrotron radiation is over 1000 times brighter than conventional sources and it is 
polychromatic and tunable, which provides a wider variety of experimental conditions (Webb & 
Roach, 2014).  
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1.4.2 X-ray Fluorescence Imaging 
X-ray fluorescence imaging (XFI) is a powerful technique used to look at elemental and 
chemical species distributions in biological tissues at various spatial resolutions (Pushie et al., 
2014). Used as an imaging method, XFI shows multiple metals simultaneously, which is an 
advantage over “single-metal” histochemistry (Popescu et al., 2009). The use of rapid-scan XFI 
has significantly increased the area that can be mapped and decreased the amount of time required 
to do so because it is a continuous raster scan of the sample. This is ideal for generating a map of 
global element distribution in large samples or whole sections of the brain (Popescu & Nichol, 
2011). XFI requires minimal sample preparation, no equipment purchase is necessary, and beam 
time can be inexpensive. Experimentally, advantages are high spatial resolution, a wide array of 
elements can be examined, and data can be quantified. This technique is non-destructive and thus, 
the same samples can be subsequently analysed using a different technique like histology.  
Tissue sections are collected on plastic, metal-free coverslips. The incident energy of the 
beam is selected and fixed so that all desired elements with K-shell absorption edges below the 
incident energy will be excited. A common incident energy is 13 keV, which can image elements 
with atomic numbers between 15 (phosphorous) and 34 (selenium). When the incident X-ray beam 
hits the sample, k-shell electrons of absorber atoms are excited and ejected in to the continuum, 
leaving a hole that is unstable. An outer shell electron will fall in to fill the core hole and this 
movement generates a fluorescent photon of a specific energy. A detector placed near the sample 
collects the X-ray fluorescent photons. To see the distribution of the element of interest, the 
specific k-edge emission energy of the element of interest is windowed on and the emitted 
spectrum is analyzed. Because XFI is based on the physics of the atom, every atom of the element 
excited by the beam will emit a fluorescent photon, regardless of its chemical state, oxidation state, 
or bound state (Popescu & Nichol, 2011). This is an advantage over iron visualization using 
Prussian blue and Turnbull because these histological stains are not reliable in detecting heme iron 
and iron tightly bound to other compounds in tissues (Meguro et al., 2007; Stuber et al., 2014). 
Since all chemical forms of an element are detected simultaneously, chemically selective 
imaging is one method that can be used to differentiate between chemical forms. To do this, 
multiple incident energies are selected carefully to detect various chemical forms and a fluorescent 
map is collected at each energy. This method of imaging uses the sensitivity of near-edge spectra 
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to chemical species, but requires a prior knowledge of the probable composition of the element in 
the brain (Pushie et al., 2014). 
The distribution of elements in human MS active lesions of different patterns in tissues 
obtained post mortem or at biopsy, has yet to be studied using XFI. XFI can provide further 
detailed information to substantiate MRI and histological data about the subcellular regulation of 
elements within lesions and normal-appearing white matter (PPWM) in MS lesions.  
1.4.3 Fourier-transform Infrared Microspectroscopy 
Various regions of the CNS can be differentiated using Fourier-transform infrared (FTIR) 
microspectroscopy based on the presence or absence of myelin (Caine, Heraud, Tobin, 
McNaughton, & Bernard, 2012). Chemical changes that underlie the process of demyelination in 
MS active lesions are reflected in the infrared spectrum as variations in band shapes and intensities 
of particular macromolecular functional groups (Caine et al., 2012). The infrared (IR) region of 
the electromagnetic spectrum lies just beyond the visible spectrum in the longer wavelength and 
lower frequency region. Mid-IR spectroscopy looks at molecular vibrations of internal (intra-) 
molecular bonds or of bonds between (inter-) molecules. The mid-IR region, specifically, spans 
the wavelength and wavenumber range of 2.5 µm (4000 cm-1) to 25 µm (400 cm-1). The 
wavenumber, expressed in cm, is the reciprocal of the wavelength and is typically used to interpret 
mid-IR spectra (Chalmers, 2011).  
Modern IR spectroscopy is performed with a Michelson interferometer that is faster and 
has better signal to noise than dispersive mid-IR spectrometers. A Michelson interferometer has a 
scanning mirror that produces constructive and destructive interference patterns as it changes 
position, resulting in an interferogram. Fourier transform is a mathematical tool that is required to 
transform the interferogram into an absorbance spectrum (Chalmers, 2011).  
When molecules are interrogated, they will absorb mid-IR radiation occurring at a 
frequency corresponding to the molecular vibrations and exhibit a characteristic absorption band 
(Chalmers, 2011). All organic functional groups have specific FTIR absorption bands, and 
particularly strong absorptions for fatty acyl moieties (methyl and methylene groups), proteins 
(amides I and II), and phosphate groups (nucleic acids, protein), which all fall within the mid-IR 
range. The FTIR spectra account not only for the chemical nature of cell molecules, but also for 
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their conformations (Goormaghtigh, Ruysschaert, & Raussens, 2006; Navea, Tauler, 
Goormaghtigh, & de Juan, 2006; Oberg, Ruysschaert, & Goormaghtigh, 2004).  
Only two previous studies have used FTIR to study MS samples and both relied on autopsy 
samples from MS patients in the chronic stage of the disease (Choo, Jackson, Halliday, & Mantsch, 
1993; LeVine & Wetzel, 1998). Since FTIR can provide in situ chemical information, this 
technique is ideal for analysing biopsies because it provides more insight into the earliest chemical 
changes occurring in MS lesions.  
1.5 General Hypothesis and Research Objectives 
1.5.1 General Hypothesis  
The distribution of elements and markers of oxidative damage can be used as biomarkers 
to distinguish between the two most common patterns of MS lesions.  
1.5.2 Research Objectives 
My first research objective was to determine whether iron levels in active lesions of the 
most common MS immunopatterns, II and III, were different in post-mortem human brain tissue. 
Then we analyzed the localization of iron within the lesions and looked at the type of iron species 
present. To carry out this objective, I: 
a) Used histopathology to classify and immunopattern active lesions and differentiate active 
lesions from PPWM. 
b) Used XFI to localize iron and quantify levels of iron in MS immunopatterns II and III. 
c) Used chemically specific imaging to differentiate between various chemical forms of iron. 
My second research objective was to examine oxidative damage in active MS lesions in human 
MS biopsies to determine whether there are differences between lesions and PPWM. To do this, I: 
a) Used histopathology to determine the demyelinating activity of lesions and to differentiate 
between lesions and PPWM. 
b) Used XFI to localize iron, sulphur, and phosphorous in MS biopsies. 
c) Used chemically specific imaging to determine the iron species present. 
d) Used FTIR to localize and quantify products of oxidation. 
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Figure 1.1 A characteristic infrared spectrum of a biological sample displaying major 
macromolecular functional groups. 
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Chapter 2 Active Lesions in Immunopatterns II and III Multiple Sclerosis Display a 
Differential Iron Distribution 
2.1 Introduction 
Significant advancements in understanding the pathogenesis of multiple sclerosis (MS), 
the disease’s evolution, its clinical, pathological and radiological features have changed and 
shaped the definition of MS as a disease since the 19th century when Jean-Martin Charcot first 
described MS. Poser et al. postulated in 1982 that MS may not be a single disease (Poser, Raun, 
& Poser, 1982), but it was not until 2000 when this hypothesis was first supported by a pathological 
study demonstrating that early active lesions in MS are heterogeneous (Lucchinetti et al., 2000). 
This pathological heterogeneity suggests that the targets of injury and mechanisms of 
demyelination are different in disease subgroups, and classifies the lesions and the lesion-bearing 
MS patients in four distinct immunopatterns. Immunopatterns II and III are the most common, 
encompassing more than 80% of all MS patients (Lucchinetti et al., 2000), and are the focus of my 
study.  
Iron has important roles in the central nervous system (CNS) such as the production and 
maintenance of myelin, and the mismanagement of iron can result in brain damage. It is presently 
unknown if and how iron accumulation or iron deficiency contribute to MS pathogenesis.  
2.1.1. Iron in MS lesions 
Oxidative stress is believed to play a significant role in the pathogenesis of MS where 
oxidized DNA and lipids are found in oligodendrocytes, myelin, astrocytes and axons (Haider et 
al., 2011). Free radicals damage subunits I and IV of the mitochondrial respiratory chain complex 
IV (cytochrome c oxidase; COX) and this is illustrated by the reduced expression of COX I and 
COX IV in oligodendrocytes, axons, and astrocytes in MS lesions (Mahad et al., 2008). 
Interestingly, mitochondrial defects and more severe oxidative damage are observed in 
immunopattern III MS lesions (Mahad et al., 2008). The oxidative stress-induced mitochondrial 
injury emphasizes the leakage of electrons from the respiratory chain and the production of reactive 
oxygen species, increase the energy demands and cause the hypoxia-like tissue damage in pattern 
III lesions of MS patients (Mahad et al., 2008). 
What exactly causes the production of ROS and mitochondrial damage is currently 
debatable. One hypothesis is that microglia and macrophages produce these free radicals during 
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the inflammation-induced oxidative burst (Fischer et al., 2012). Another possibility is that 
accumulation of excess iron damages the tissues because of the iron’s ability to react with oxygen 
and produce harmful reactive oxygen species (ROS) (Meguro et al., 2007) that cause oxidation of 
lipids (Haider et al., 2011; Hametner et al., 2013), proteins (LeVine & Wetzel, 1998) and DNA 
(Haider et al., 2011). Indeed, early research has described abnormal iron deposits in the periplaque 
area in MS autopsy samples but not in the control tissues suggesting that damage in MS may be 
related to iron accumulation (Craelius, Migdal, Luessenhop, Sugar, & Mihalakis, 1982). Defining 
the spatial and temporal distribution of iron is critical for understanding its role in MS pathology. 
LeVine (1997) et al. have demonstrated the presence of iron within macrophages in demyelinated 
white matter and concluded that iron accumulation at these sites may be involved in oxidative 
damage (LeVine, 1997). Hametner et al (2013) have compared non-heme iron in different MS 
plaque types and found that late active lesions contained most iron. Therefore, the distribution and 
content of iron may be used to differentiate among different lesion types.  
Why not all CNS cells are equally affected is also uncertain. Iron in the human brain is 
mostly bound to ferritin and sheltered in a soluble, bioavailable form (Friedman et al., 2011; Theil, 
1987). Ferrous iron enters the ferritin protein shell, is oxidized to ferric iron in the ferroxidase 
centres of the H-ferritin subunits, then mineralized to ferrihydrite and added to the iron core of 
ferritin by the L-ferritin subunits (Arosio, Carmona, Gozzelino, Maccarinelli, & Poli, 2015; 
Chasteen & Harrison, 1999; Theil, 2013). The deposition of the excess iron in ferritin serves as a 
protective mechanism by impairing the ferrous iron to participate in the Fenton reaction (Friedman 
et al., 2011). In addition, several molecules such as superoxide dismutase and glutathione have the 
ability to reduce ROS and serve as important cellular antioxidant defenses. An increased 
susceptibility to oxidative stress and/or an inability to properly upregulate their antioxidant defense 
mechanisms (van Horssen, Schreibelt, Drexhage, et al., 2008), may render the oligodendrocytes 
more susceptible to apoptosis in immunopattern III MS. 
2.1.2. Visualizing Iron in MS  
The current gold standard for visualizing iron in the brain is histochemistry. The 
histological demonstration of iron is performed using the Perls’ and Turnbull histochemical 
methods, which detect ferric and ferrous iron, respectively. The Perls’ staining uses acid-
ferrocyanide that reacts with ferric iron to form the insoluble Prussian blue. Similarly, the Turnbull 
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method is based on the reaction between acid-ferricyanide and free ferrous ions (Meguro et al., 
2007). The DAB enhancement of both Perls’ and Turnbull’s histochemical methods allows for a 
better visualization of iron. The study of iron in the brain has been hindered by the limitations of 
histochemistry: iron histochemistry cannot detect the heme iron and is not quantifiable. X-ray 
fluorescence imaging (XFI) addresses all the limitations of histochemistry: it is element specific, 
quantitatively detects all chemical forms of iron and can simultaneously map additional metals 
which is important when considering the relationship between iron and other chemical elements 
(Popescu et al., 2009a; Popescu et al., 2009b; Popescu et al., 2009c; Popescu and Nichol, 2011; 
Pushie et al., 2014). 
Magnetic resonance imaging (MRI) has been proposed as the imaging technique of choice 
to detect iron in vivo and MRI sequences such as phase and R2* multi-gradient echo (GRE) and 
susceptibility weighted imaging (SWI) have been used to further the understanding of the role of 
iron in MS pathogenesis (Bagnato et al., 2011; Zheng, Nichol, Liu, Cheng, & Haacke, 2013; 
Zhong, Utriainen, Wang, Kang, & Haacke, 2014). By comparison with histochemistry, phase and 
R2* GRE imaging have localized iron to microglia and macrophages at the lesions’ edge and to 
oligodendrocytes in the periplaque white matter (PPWM) (Bagnato et al., 2011; Mehta et al., 
2013). Phase imaging has also been used to quantify iron in macrophages in an attempt to 
differentiate between macrophages associated with pro- or anti-inflammatory phenotypes within 
lesions (Mehta et al., 2013). Iron quantification with MRI is however unreliable because of 
formalin fixation, the water content, and tissue composition can influence these measurements 
(Zheng et al., 2013). While XFI cannot be used to detect iron in vivo, it should be considered the 
gold standard upon which new iron-sensitive and iron-specific MRI sequences are developed.  
2.1.3. Hypothesis 
I hypothesized that there is iron heterogeneity in MS, and that the oxidative stress that 
drives the mitochondrial injury and demyelination in immunopattern III MS is caused by iron 
accumulation.  
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2.2 Materials and Methods 
2.2.1 Sample Preparation 
Human autopsy and biopsy MS tissues were retrieved from the Department of Laboratory 
Medicine and Pathology, University of Saskatchewan, from the Mayo Clinic in Rochester, MN, 
USA, and from the University of Vienna, Austria. Tissues were fixed in 10% formalin, embedded 
in paraffin and sectioned with an ultra-thin semi-automatic microtome (KD-3358). Sections were 
floated in a 30% ethanol bath for approximately five minutes, then placed in a water bath (Leica 
HI 1210) set at 42-43°C. Five and 15 micrometer (µm)-thick sections were collected on glass slides 
and plastic coverslips (Thermanox) for immunohistochemistry and synchrotron imaging, 
respectively. Sections were dried overnight at room temperature.  
2.2.2 Histology and Immunohistochemistry 
Sections were stained with Luxol-fast blue/hematoxylin and eosin (LFB-HE) (Kluver & 
Barrera, 1953) to visualize myelin and H&E to visualize the tissue and cell morphology (Mallory, 
1938). Immunohistochemistry was performed using an Avidin-Biotin technique on serial sections. 
Five µm sections were deparaffinised in xylene and rehydrated through graded alcohol. 
Endogenous peroxidase activity was blocked by pre-treating the sections with 3% hydrogen 
peroxide (30% stock H2O2 RICCA Chemical Co., Cat. No. 3821.7-32) in absolute methanol.  
Antigen retrieval was performed by immersing the sections in 10mM citric acid buffer (pH 6) and 
steaming them for 45 minutes in a vegetable steamer (Black and Decker). Once antigen retrieval 
was complete, sections were cooled and coverplated. Sections were blocked with 10% fetal bovine 
serum (ATCC, Cat. No. 30-2020) for 15 minutes at room temperature and incubated overnight at 
4°C with the primary antibodies listed in Table 1.  
Sections were then incubated for one hour at room temperature with the following biotinylated 
secondary antibodies diluted with 3% human serum (Cedarlane, Cat. No. H4522-100mL) in 10% 
FBS: donkey anti-rabbit IgG (1:200, Jackson Immuno Lab, Cat. No. 711-065-152), sheep anti-
mouse IgG (1:200, GE Healthcare, Cat. No. RPN1001), and rabbit anti-goat (1:200, Jackson 
Immuno Lab, Cat. No. 305-65-003). Sections were then incubated with Avidin-Peroxidase (1:100, 
Sigma-Aldrich, Cat. No. A3151) for one hour at room temperature, followed by development with 
3, 3’-Diaminobenzidine (DAB) Tetrahydrochloride Hydrate (Amresco, Cat. No. D430-10mg). The 
DAB reaction was stopped in tap water and sections were counterstained with Mayer’s 
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Hematoxylin (Sigma-Aldrich, Cat. No. MHS16-500), differentiated in an acid alcohol solution 
(0.5% HCl in 70% ethanol) for 30 seconds, and blued in Scott’s solution for 10 minutes at room 
temperature. This was followed by dehydration through graded alcohols to xylene and finally 
mounting with Cytoseal-60 (Fisher Scientific, Cat. No. 8310-4).    
2.2.3. Characterization of Immunopatterns 
 Active lesions and periplaque white matter (PPWM) regions were identified and 
immunopatterned as previously described (Lucchinetti et al., 2000; Metz et al., 2014). Active 
lesions were demyelinated lesions infiltrated by macrophages containing myelin degradation 
products. PPWM was the white matter immediately surrounding the demyelinated lesions. While 
myelin is preserved in the PPWM, these regions often display signs of injury such as inflammation 
and microglial activation (Moll et al., 2011)  
2.2.4. X-ray Fluorescence Imaging 
Rapid scanning XFI and microprobe XFI were carried out on beam lines (BL) 10-2 and 2-
3, respectively at the Stanford Synchrotron Radiation Lightsource (SSRL). Serial sections, 15 μm 
thick, were placed on metal free plastic coverslips (Thermo Fisher Scientific, Cat. No. 72271). On 
BL 10-2, whole sections were imaged at 50 μm resolution, achieved with a 50 μm pinhole aperture. 
The incident energy was 12.5 keV and the dwell time 80 ms per pixel. On BL 2-3, regions of 
interest of the samples previously imaged on BL 10-2 were scanned at 3 μm resolution, using 12.5 
keV incident beam focused with Kirkpatrick-Baez (KB) focussing mirrors. Data was collected 
with a 120 ms dwell time per pixel. The samples were mounted vertically at 45° to the incident X-
ray beam and 45° to the detector, and continuously raster scanned in the beam.   
2.2.5 Chemically Specific Imaging 
Chemically specific imaging was performed at BL 2-3 to differentiate between various iron 
species in small regions of interest. Data was collected at incident energies of 7118.5 eV, 7126.5 
eV, and 7132 eV for iron-sulfur clusters, ferrous and ferric iron, respectively, using five μm 
resolution and 100 ms dwell time 
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Table 2.1 Primary antibodies used for immunohistochemistry.  
Protein target Species Dilution Source Catalogue 
Number 
Proteolipid protein 
(PLP) 
 
Mouse 1:500 AbD Serotec MCA839G 
 
Myelin-associated 
glycoprotein (MAG) 
 
Rabbit 1:500 Sigma-Aldrich HPA012499 
Myelin oligodendrocyte 
glycoprotein (MOG) 
 
Rabbit 1:1000 Abcam ab109746 
CD68 
 
Mouse 1:100 DakoCytomation M0879 
Heavy chain ferritin 
(HF) 
Rabbit 1:1000 Abcam ab65080 
Light chain ferritin (LF) 
 
Goat 1:300 Abcam ab110017 
Transferrin (TF) 
 
Rabbit 1:1000 Sigma-Aldrich HPA005692 
Transferrin receptor 
(TFRC) 
 
Rabbit 1:500 Sigma-Aldrich HPA028598 
Complement C9neo 
antigen (C9neo) 
 
Mouse 1:200 Professor Morgan 
from Cardiff, UK  
Clone B7 
Terminal complement 
complex (TCC) and C9 
Rabbit 
anti-
human 
 
1:200 Professor Morgan 
from Cardiff, UK 
 
- 
Terminal complement 
complex (TCC) and C9 
Rabbit 
anti-rat 
1:200 Professor Morgan 
from Cardiff, UK 
 
- 
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2.2.6 Image Analysis 
The XFI images were generated using Microanalysis Toolkit (Samuel Webb, SSRL; 
http://www.sams-xrays.com/smak). All images were normalized to I0 to account for variations in 
the incoming beam intensity. SMAK was also used to quantify iron content in the samples. 
2.2.7 Iron Quantification 
Histology slides were scanned at 40x magnification using an Olympus VS110 virtual slide 
scanner microscope. Whole maps were saved as .jpeg files on which regions of interest of active 
lesions and PPWM were identified and outlined. XFI images were generated using Microanalysis 
Toolkit. Histology and XFI maps were displayed side by side, and the regions of interest were 
masked on the XFI maps using the histology maps as guides. Values for iron from each mask were 
collected for further statistical analyses.   
2.2.8 Statistical Analysis 
Statistical analysis was performed at the Mayo Clinic. Comparisons of pattern II vs. pattern 
III were carried out using generalized estimating equations (GEE) models with an 'exchangeable' 
correlation structure in order to take into account that regions from the same subject are likely to 
be correlated. The metal values were log transformed in order to assist with the interpretation of 
the model output. Analyses using untransformed metal values yielded similar results.   
2.3 Results  
2.3.1 Pathological Characteristics of Immunopatterns II and III 
Nine cases were classified as immunopattern II (Fig. 2.1) and 18 cases as immunopattern 
III (Fig. 2.2). Lesions in both immunopatterns II and III were infiltrated by activated 
macrophages/microglia (Fig. 2.1D, and E, 2.2D, and F). Important histological features of 
immunopattern II lesions included complement activation onto myelin sheaths (Fig. 2.1G, arrows) 
and within macrophages (Fig. 2.1H, arrows), which was not observed in immunopattern III lesions 
(Fig. 2.2E). Immunopattern III lesions showed preferential loss of MAG compared to PLP (Fig. 
2.2B and C), while all myelin proteins were equally lost in immunopattern II MS (Fig. 2.1B and 
C).  
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Figure 2.1 Activation of complement on myelin and within macrophages and equal loss of 
myelin proteins are characteristic for immunopattern II MS lesions. The demyelinated lesion 
is illustrated by the (A) absence of the blue histological stain (LFB-HE), as well as the lack 
of immunoreactivity for (B) proteolipid protein (PLP) and (C) myelin-associated 
glycoprotein (MAG). D. Macrophages infiltrate the demyelinated lesion (KiM1P). E) At 
higher magnification, foamy macrophages (arrows) are seen perivascularly and in the 
surrounding tissue (KiM1P). F) The activation of complement is a hallmark feature of pattern 
II MS lesions. Higher magnification shows that activated complement is localized on myelin 
sheaths (G, arrows) and within macrophages (H, arrows). Scale bar: (A-D, F) 2 mm; (E, G 
& H) 50 µm. 
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Figure 2.2 Preferential loss of myelin-associated glycoprotein and the preservation of other 
myelin proteins is characteristic for immunopattern III MS lesions.  A) The demyelinated 
lesion is illustrated by the absence of the blue histological stain (LFB-HE). B) Proteolipid 
protein (PLP) is relatively preserved, but PLP debris is seen within macrophages (inset). C) 
Myelin-associated glycoprotein is preferentially lost (MAG). D) Macrophages infiltrate the 
demyelinated lesion (KiM1P). E) Activation of complement is absent (C9neo). F) High 
magnification shows the sea of macrophages (arrows) within the lesion (KiM1P). Scale bar: 
A-E) 2 mm; F) 50 µm; inset in B) 5 µm 
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2.3.2 Immunopattern II Lesions Contained More Iron Than Immunopattern III Lesions and 
Iron Localized Within Macrophages 
 Rapid-scanning XFI showed that immunopattern II MS lesions (Fig. 2.3B) contained more 
iron than immunopattern III MS lesions (Fig. 2.3F), and this difference attained statistical 
significance (p=0.003) (Fig. 2.4). The difference between the iron content of the PPWM in 
immunopatterns II and III was not significantly different (p=0.16). Immunopattern II lesions had 
more iron than immunopattern II PPWM (Fig. 2-3B), while iron was decreased in immunopattern 
III MS lesions when compared to immunopattern III PPWM (Fig. 2-3F). This distribution was also 
reflected in the high resolution iron maps for immunopattern II (Fig. 2.3C and D), and 
immunopattern III (Fig. 2.3G and H), respectively. Micro-focused X-ray fluorescence showed that 
iron in immunopattern II localized to discrete structures (Fig. 2.3C), identified as macrophages 
when iron maps were compared to the adjacent immunohistochemical-stained sections. These 
macrophages also contained intracytoplasmic granules immunoreactive for myelin and 
complement (Fig. 2.2B inset and 2.1H). Myelin-laden macrophages in active immunopattern III 
lesions did not contain iron (Fig 2.3G). The PPWM of both patterns showed a patchy distribution 
of iron (Fig. 2.3D and H) consistent with the iron being localized to oligodendrocytes (Connor & 
Menzies, 1996; Todorich et al., 2009).  
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Figure 2.3 Immunopattern II lesions contain more iron than immunopattern III lesions and 
iron localizes to macrophages. Immunohistochemical maps of immunopattern II (A) and III 
(E) MS show the demyelinated lesions (blue outlines) and the PPWM regions (green 
outlines). Rapid-scanning XFI shows increased iron in the active lesion of immunopattern II 
(B), but not immunopattern III (F) MS. High resolution XFI shows that iron is localized 
within macrophages in immunopattern II lesions (C) while iron in the PPWM has a patchy 
appearance (D). High resolution XFI shows absence of iron in immunopattern III lesions (G), 
while iron in the PPWM has a patchy appearance (H). Intensity scale bars represent the 
normalized total Kα fluorescence counts, proportional to total metal present, from blue 
(lowest) to red (highest). Scale bar: A, B, E, F) 2 mm; C, D, G, H) 90 µm. 
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Figure 2.4 Statistical analysis of iron in active lesions show more iron in immunopattern II 
lesions. Iron levels were significantly higher in immunopattern II lesions (IP II) as compared 
to immunopattern III lesions (IP III). Estimate (95% CI): 0.56 (0.19, 0.94); p =0.003.  
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2.3.3 Ferric Iron is the Predominant Iron Species in Macrophages 
Chemically specific imaging of iron showed that the ferrihydrite of ferritin (ferric iron 
coordinated with six oxygen atoms) is the predominant iron species in all samples. Ferrihydrite 
was most abundant in immunopattern II lesions (Fig. 2.5C), followed by the PPWM of 
immunopattern II (Fig. 2.5F) and immunopattern III (Fig. 2.5L) MS, and immunopattern III lesions 
(Fig. 2.5I). Fe-S clusters (Fig. 2.5A, D, G, and J) and ferrous iron (Fig. 2.5B, E, H, K) were 
unremarkable in lesions and PPWM of both immunopatterns. 
2.3.4 H-Ferritin Localizes to Nuclei of Oligodendrocytes in PPWM of Immunopattern III 
Lesions 
Both H-ferritin and L-ferritin were localized to the cytoplasm of macrophages in 
immunopattern II and III MS lesions (Fig. 2.6A, C, E, and G), while L-ferritin mainly stained the 
microglia in the PPWM of both immunopatterns (Fig. 2.6D and H). Immunoreactivity for H-
ferritin in the PPWM was different between the two immunopatterns. In immunopattern II PPWM, 
H-ferritin immunoreactivity was identified in the cytoplasm of oligodendrocytes as a brown rim 
around the nuclei (Fig. 2.6B, arrows), while in immunopattern III PPWM, H-ferritin 
immunohistochemistry stained the nuclei of oligodendrocytes (Fig. 2.6F, arrows). 
Oligodendrocyte counting showed that immunopattern II cases had an approximately 10-fold 
increase in the odds of having no immunoreactivity to H-ferritin in the nuclei [95% CI, 11.30 (6.33, 
21.41), p<0.001).  
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Figure 2.5 Ferrihydrite of ferritin is the predominant iron species in all samples and is 
highest in immunopattern II lesions. Iron-sulfur clusters (A, D, G, J) and ferrous iron (B, E, 
H, K) are negligible constituents of the overall iron environment in lesions (A, B, G, H) and 
PPWM (D, E, J, K) of both immunopattern II (A, B, D, E) and immunopattern III (G, H, J, 
K) MS. The ferrihydrite of ferritin is prominent and localized to macrophages immunopattern 
II lesions (C). Ferrihydrite in immunopattern II (F) and III (L) PPWM shows a patchy 
distribution consistent with localization to oligodendrocytes. The ferrihydrite is lowest in 
immunopattern III lesions (I) consistent with an iron deficient environment. Intensity scale 
bar represents the normalized total Kα fluorescence counts, proportional to total metal 
present, from blue (lowest) to red (highest). Scale bar 100 µm. 
32 
 
 
Figure 2.6 Ferritin heavy chain (H-ferritin) localizes to oligodendrocyte nuclei in 
immunopattern III PPWM, and to the cytoplasm of oligodendrocytes in immunopattern II 
PPWM. H-ferritin is seen (A) in the cytoplasm of macrophages (arrows) in the 
immunopattern II lesion (HF), and (B) in the cytoplasm of oligodendrocytes (arrows) in 
immunopattern II PPWM (HF). L-ferritin immunoreactivity is positive (C) in the cytoplasm 
of macrophages (arrows) in immunopattern II lesion (HF) and (D) within microglia of 
immunopattern II PPWM (LF). H-ferritin localizes (E) to the cytoplasm of macrophages 
(arrows) in immunopattern III lesions (HF) and (F) to oligodendrocyte nuclei (arrows) in 
immunopattern III PPWM (HF). L-ferritin stains (G) macrophages (arrows) in 
immunopattern III lesions (LF) and (H) microglia in immunopattern III PPWM (LF). Scale 
bar: 10 µm; HF – H-ferritin; LF – L-ferritin. 
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2.4 Discussion 
This study shows that the pattern of iron is distinct and heterogeneous across different MS 
immunopatterns. Using cutting edge X-ray fluorescence synchrotron imaging that is sensitive and 
specific to iron (Pushie et al., 2014), I report for the first time that the distribution and content of 
iron differs between immunopatterns II and III MS lesions. It has been previously suggested that 
macrophages and microglia in early MS accumulate iron that is released from destroyed 
oligodendrocytes (Hametner et al., 2013). However, while macrophages were present and 
abundant in both immunopattern II and III active MS lesions, only those present in immunopattern 
II lesions accumulated iron. This indicates that there may be more factors, in addition to the 
previously suggested iron storage shift from destroyed oligodendrocytes to macrophages and 
microglia, that affect how macrophages accumulate or release iron. 
One possibility is that this heterogeneous iron loading of macrophages reflects their 
different polarization states (Corna et al., 2010; Mehta et al., 2013). Polarization is a spectrum of 
functional profiles that macrophages adopt depending on signals they receive from the immune 
cells. At one end of the spectrum, classically activated (or M1-polarized) macrophages are pro-
inflammatory while at the opposing end of the spectrum, alternatively activated (or M2-polarized) 
macrophages help resolve inflammation (Cairo, Recalcati, Mantovani, & Locati, 2011). M1 
macrophages, associated with the production of ROS and pro-inflammatory cytokines, sequester 
iron (Gammella, Buratti, Cairo, & Recalcati, 2014). M2 macrophages export iron out of the cell 
and decrease their ferritin levels (Gammella et al., 2014). This reduces the intracellular iron 
availability therefore blocking the formation of iron-dependent enzymes involved in the 
inflammatory response with dampening of inflammation, and increases the extracellular iron 
availability which helps to promote tissue repair (Cairo et al., 2011). Such an iron-related 
macrophage polarization dichotomy has been previously described, but attributed not to different 
mechanisms of demyelination but to the ability of macrophages to phagocytose iron and myelin: 
macrophages accumulate iron and this induces a pro-inflammatory M1-polarization state, while 
myelin ingestion prevents M1-polarization and iron uptake and converts macrophages to an anti-
inflammatory M2-polarization state (Mehta et al., 2013).  
Another possibility is that the iron heterogeneity of macrophages is an expression of the 
different mechanisms of demyelination postulated to occur in these two different MS 
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immunopatterns. Demyelination in immunopattern II MS is hypothesized to be caused by 
complement activating antibodies that target yet unknown antigens on oligodendrocytes and/or 
myelin. Accordingly, there is a striking co-localization of antibody deposition and complement 
activation on myelin in immunopattern II MS (Lucchinetti et al., 2000). Specifically, deposition 
of the complement component C1q and activation of the terminal lytic complex C5b-9 is seen 
within myelin-laden macrophages and on abnormal myelin in MS active lesions (M. H. Barnett, 
Parratt, Cho, & Prineas, 2009; Lucchinetti et al., 2000; Storch et al., 1998). C1q is responsible for 
tagging foreign pathogens and subsequently triggering the classical complement pathway that 
leads to destruction of the pathogen, and in the presence of ferrous iron ions, C1q increases its 
binding to immunoglobulins (Dimitrov, Roumenina, Doltchinkova, & Vassilev, 2007). C5 is also 
known to bind iron ions and iron is required for the conversion of C5 to activated C5b by hydroxyl 
radicals (Vogi, Nolte, & Brunahl, 1991). C5b interacts with other complement components to form 
C5b-9, which is the membrane attack complex (MAC) that forms the transmembrane pores that 
kill the targeted cell (Tegla et al., 2009). Thus, iron is essential for complement function and 
terminal lytic complex assembly, explaining why immunopattern II MS macrophages that 
phagocytose complement-opsonized myelin debris contain increased amounts of iron.   
In contrast to the high iron content of macrophages in immunopattern II, macrophages in 
immunopattern III MS lesions contained very little iron. Oxidative stress and mitochondrial injury 
play an important role in the pathogenesis of immunopattern III MS (Haider et al., 2011; Mahad 
et al., 2008) and it has been assumed that excess iron drives the tissue injury in immunopattern III 
MS (Hametner et al., 2013). My results however show that iron deficiency, rather than the excess 
of iron, drives the pathology of immunopattern III lesions. Iron is essential for energy production 
because it functions as a cofactor for cytochromes a, b, c, and Fe-S clusters of the mitochondrial 
respiratory chain (Todorich et al., 2009). Depletion of iron, as observed in immunopattern III 
lesions, can cause mitochondrial dysfunction by disrupting the iron-sulfur cluster biogenesis and 
production energy leading to a state of virtual hypoxia that would primarily affect demyelinated 
axons requiring an increased energy demand to maintain nerve conduction (Trapp & Stys, 2009). 
The disruption of oxidative phosphorylation also causes an increase rate of electron escape from 
the mitochondrial respiratory chain resulting in increased ROS production (Higgins et al., 2010) 
with oxidation of phospholipids and DNA (Haider et al., 2011). Mitochondrial dysfunction can 
activate apoptotic pathways (Zhang et al., 2005) and the immunopattern III-characteristic 
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oligodendrocyte apoptosis (Aboul-Enein et al., 2003). This is also reinforced by the finding that, 
unlike oligodendrocytes in immunopattern II PPWM where H-ferritin is expressed in the 
cytoplasm, the H-ferritin in immunopattern III PPWM oligodendrocytes is localized to the nuclei. 
This is consistent with the translocation of H-ferritin from the cytoplasm to the nuclei of 
oligodendrocytes where it binds to the DNA in order to protect it from ROS-induced damage 
(Alkhateeb & Connor, 2010; Thompson, Fried, Ye, Boyer, & Connor, 2002). 
The most important study limitation is the use of formalin-fixed paraffin embedded tissue 
equally affecting both iron histochemistry and XFI. Formalin fixation is routinely used in 
pathology labs to preserve the tissue and prevent decomposition and autolysis (Thavarajah, 
Mudimbaimannar, Elizabeth, Rao, & Ranganathan, 2012) and is known to leach metals from 
tissues, although its extent is debatable (Bush, Moyer, Batts, & Parisi, 1995; Chua-anusorn, Webb, 
Macey, Pootrakul, & St Pierre, 1997; Schrag et al., 2010). It is expected that the paraffin 
embedding process accentuates this leaching phenomenon through the exposure of tissues to 
alcohol, xylene and increased temperatures. The paraffin embedding process also oxidizes metals 
explaining perhaps why no ferrous iron was detected and raising questions about the ability of 
Turnbull stain to exclusively detect ferrous iron in formalin fixed paraffin embedded tissue 
sections (Hackett et al., 2011). 
MS is heterogeneous with respect to clinical, genetic, radiographic, and pathologic 
features, and it seems increasingly plausible that MS may be a cluster of diseases with similar 
clinical presentation. The challenge is now to identify surrogate MRI, clinical, genetic, serological 
and/or CSF markers that would correlate with immunopatterns in the non-biopsied MS patient 
population. I show here that lesions in immunopattern II MS contain significantly more iron than 
lesions of immunopattern III MS, and this novel observation paves the way for developing new or 
using existing iron-sensitive MRI techniques (Bagnato et al., 2011; Haacke et al., 2009) to stratify 
the patients with early MS. Future studies will have to validate such iron-sensitive MRI techniques 
by comparing the MRI with the XFI of formalin fixed brain slices (Popescu et al., 2009; Zheng et 
al., 2013). 
The obvious practical application of the heterogeneity concept is the design of novel 
therapeutic strategies specifically tailored to each immunopattern. In support of this hypothesis, 
immunopattern II MS has been shown to be uniquely responsive to plasma exchange for treatment 
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of steroid unresponsive fulminant MS relapses, while this treatment does not benefit either 
immunopattern I, or immunopattern III MS patients (Keegan et al., 2005). The proposal of iron 
chelation therapy in MS is controversial (Creange, Lefaucheur, Balleyguier, & Galacteros, 2013; 
Stephenson et al., 2014; Weigel, Lynch, & LeVine, 2014), and stems from the premise that iron 
accumulates in MS lesions. Currently, there are three approved iron chelators for therapeutic use: 
deferoxamine, deferasirox, and deferiprone (Weigel et al., 2014). Only deferoxamine has been 
tested in human MS patients and the outcome of the most recent study has reported that one out of 
nine study patients improved, while the disability of five patients worsened (Lynch, Fonseca, & 
LeVine, 2000). My results also argue against indiscriminate iron chelation in all patients with early 
acute MS. Chelation therapy may be beneficial in immunopattern II MS where it would decrease 
the C1q binding to the antibodies and impair the cleavage of C5 therefore impeding the formation 
of the terminal lytic complex and protecting oligodendrocytes and myelin. However, the chelation 
of the minimal amounts of iron present in immunopattern III MS lesions may supress the already 
challenged metabolic activity of oligodendrocytes thereby accelerating their death (Zhang et al., 
2005). 
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Chapter 3 Oxidative Injury in Active Multiple Sclerosis Lesions 
3.1 Introduction 
Multiple sclerosis (MS) is a disease of the central nervous system (CNS) that causes 
disability in young people between the ages of 15 and 40 and is twice as likely to occur in females 
than males (Hader & Yee, 2007; MS Society of Canada, 2016). In MS, the oligodendrocyte and 
its product, the myelin sheath protecting axons, are targeted and destroyed by the body’s immune 
system leading to the formation of demyelinated plaques or lesions. Pathological features of MS 
change over time and differ in the early versus chronic phases of the disease (Popescu et al., 2013). 
Active lesions predominate in early, relapsing remitting MS, but decline to nearly zero percent in 
long-standing chronic progressive MS where inactive lesions become predominant. Therefore, the 
active lesion is the earliest pathological change occurring in MS and represents the pathological 
substrate of attacks in relapsing-remitting MS (RRMS) (Frischer et al., 2015). This shows the 
complex and dynamic nature of MS and reinforces the idea that MS is not driven by a single 
mechanism of action that only one therapeutic strategy can solve. For example, anti-inflammatory, 
immunomodulatory, or immunosuppressive therapies tend to benefit patients in the early phase of 
the disease more than patients who are in the progressive stage (Lassmann et al., 2007). 
3.1.1 Oxidative Injury and MS 
The brain is highly susceptible to oxidative injury due to its high concentrations of lipids 
and unsaturated fatty acids (Friedman et al., 2011). Lipid peroxidation occurs when a reactive 
oxygen species (ROS) takes an electron from an unsaturated fatty acid in the lipid membrane, 
resulting in an unstable lipid radical that can react in a chain reaction with oxygen to form lipid 
hydroperoxides (McGill & Jaeschke, 2013).  Oxidative stress is believed to play a significant role 
in the pathogenesis of MS: oligodendrocytes have been shown to be more vulnerable to oxidative 
stress than other glial cells in vitro (Mitrovic, Ignarro, Montestruque, Smoll, & Merrill, 1994); the 
highly toxic end product of lipid oxidation, 4-hydroxy-2-nonenal (HNE), is increased in 
demyelinated MS lesions compared to the periplaque white matter (PPWM) (van Horssen et al., 
2008) and oxidized phospholipids are localized to myelin, oligodendrocytes, and acutely injured 
axons in actively demyelinating lesions (Haider et al., 2011). Severe oxidative damage to cell 
membranes can trigger cell death by apoptosis or necrosis (Fuchs, Perez-Pinzon, & Dave, 2014), 
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which may explain the characteristic immunopattern III MS oligodendrocyte apoptosis 
(Lucchinetti et al., 2000). 
Oxidative stress is more commonly seen in immunopattern III MS lesions, which are 
characterized by a distinctive loss of myelin-associated glycoprotein (MAG) compared to other 
myelin proteins such proteolipid protein (PLP), myelin basic protein (MBP) or myelin 
oligodendrocyte glycoprotein (MOG). MAG is a transmembrane glycoprotein that is located in the 
innermost layer of the myelin sheath surrounding the axon and plays an important role in 
oligodendrocyte-axon interactions (Quarles, 2007). Its preferential destruction is hypothesized to 
be the result of metabolic disturbances in oligodendrocytes (Popescu & Lucchinetti, 2012b) 
indicating “dying-back” oligodendrogliopathy, in which the earliest pathological changes occur in 
the oligodendrocyte processes distal to the cell body. Oligodendrocytes are highly metabolic cells 
that require much energy in the form of adenosine triphosphate (ATP), which is produced in 
mitochondria (Todorich et al., 2009). Important mitochondrial proteins involved in oxygen 
consumption and ATP synthesis have been shown to be defective in MS lesions (Mahad et al., 
2005), and this oxidative damage –induced mitochondrial injury is postulated to drive tissue injury 
in MS (Haider et al., 2011). Mitochondria produce ROS normally as a by-product of cellular 
respiration, but only when the production of ROS overwhelms the antioxidant system, does ROS 
mediate oxidative damage to membrane lipids, deoxyribonucleic acid (DNA), and proteins (van 
Horssen et al., 2008).  
The oligodendrocyte is the CNS cell that stains most robustly for iron and many of the 
enzymes involved in ATP synthesis, and in the synthesis of cholesterol and lipids integral for the 
myelin’s composition use iron as a cofactor (Todorich et al., 2009). Excess cellular iron is safely 
stored as ferric iron in ferritin (Hulet et al., 1999) to protect the cell from the redox-active ferrous 
iron, which can form toxic ROS via the Fenton reaction (Hametner et al., 2013). It has been 
suggested that destruction of iron-rich myelin and oligodendrocytes in MS lesions leads to a 
liberation of iron into the extracellular space, propagating a wave of iron-induced oxidative 
damage (Hametner et al., 2013). 
Elemental sulphur is a component of sulfatides, which are important constituents of myelin 
(Stuber et al., 2014). Sulphur is also part of many enzymes and antioxidant molecules, such as 
glutathione (Mukwevho et al., 2014). Oligodendrocytes and endothelial cells in MS lesions have 
39 
 
been shown to have low levels of antioxidant enzymes, which may render oligodendrocytes more 
susceptible to oxidative damage (van Horssen et al., 2008). Sulfur is also an important component 
of Fe-S clusters, which are involved in crucial cell functions such as respiration, catalysis, and 
redox reactions (Todorich et al., 2009; Ye & Rouault, 2010), and improper Fe–S cluster protein 
formation can lead to iron overload in mitochondria in mammalian cells (Rouault, 2012). 
Myelin is made of 70% lipids in the form of cholesterol, galactolipid, and phospholipid 
(Stuber et al., 2014), and about 80% of phosphorous in white matter and 60% in gray matter is 
located in phospholipids (Stuber et al., 2014), providing a good biomarker for myelin health in 
MS. Phospholipids, and cholesterol are particularly vulnerable to oxidative damage (Ayala, 
Munoz, & Arguelles, 2014). Phosphorous is also found in DNA in phosphomonoester and 
phosphodiester proteins. Phosphocreatine and nucleoside phosphates like ATP and adenosine 
diphosphate (ADP), important in energy transfer, contain phosphorous.  
Reactive oxygen species causing mitochondrial injury may be an important tissue injury 
mechanism. Oxidized lipids and proteins stand as oxidative damage markers. The lack of 
techniques, which can reliably quantify and image such biochemical species, has been a long-
standing obstacle to the study of oxidative stress contribution to MS. To date, the most convincing 
data showing tissue oxidative damage has been acquired immunohistochemically (Haider et al., 
2011). However, this approach leads to false-positive results, lacks quantification sensitivity and 
specificity as it is based on staining densitometry, and fails to identify all oxidized proteins and 
lipids.  
Characteristic marker bands for oxidized lipids and proteins are present in Fourier 
transform infrared (FTIR) spectra. FTIR microspectroscopy is a technique suitable to study such 
biological processes in situ due to the wealth of molecules which absorb light across the mid-
infrared range (Caine et al., 2012). As the technique is non-destructive, it is easily compatible with 
histology. Oxidative damage in MS lesions has been studied in the past using infrared spectroscopy 
(Choo et al., 1993; LeVine & Wetzel, 1998). One study used autopsy samples from MS patients 
to detect and localize free radical damage in active MS lesions, but did not provide either the 
demyelinating staging or the criteria used to classify active lesions (LeVine & Wetzel, 1998). 
Despite detecting tissue oxidative damage it is not clear at which stage of MS lesion development 
the reported changes take place. Past studies often had to rely on autopsy tissues collected from 
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patients in the chronic stage of the disease (De Groot et al., 2001) leaving a gap in information 
about pathological processes occurring at the onset of MS. A brain biopsy is the removal of brain 
tissue from a living patient for immediate pathological examination. Although brain biopsies are 
rarely used as part of MS diagnosis, they are sometimes performed to exclude other pathologies 
like tumours (Kuhlmann, Lassmann, & Bruck, 2008). Biopsy samples are often collected from MS 
patients near the first symptom onset, during the first demyelinating episode and present a novel 
opportunity to study the involvement of oxidative damage in the earliest demyelinating stages. To 
my knowledge, this is the first FTIR study performed on MS brain biopsy tissues. 
3.1.2. Aim of Study 
My hypothesis is that oxidative damage to lipids and proteins is present in the earliest MS 
lesion stages. The aim of this study is to analyze the role of oxidative stress in the pathology of 
MS.  
3.2 Materials and Methods 
3.2.1 Sample Preparation 
Six patient biopsies with the diagnosis of demyelination consistent with MS confirmed by 
a certified neuropathologist were retrieved from the Department of Laboratory Medicine and 
Pathology of the Saskatoon Health Region. Five, ten, and fifteen micron-thick sections were cut 
with an ultra-thin semi-automatic microtome (Zhejiang Jinhua Kedi Instrumental Equipment Co., 
KD-3358). Sections were floated in a 30% ethanol bath for approximately five minutes, then 
placed in a water bath (Leica HI 1210) set at 42-43°C. Five micron-thick sections were collected 
on glass slides for histology and immunohistochemistry. Ten micron-thick sections were collected 
on calcium fluoride optical windows for mid-infrared imaging and fifteen micron-thick sections 
were collected on metal-free plastic coverslips for X-ray fluorescence imaging. These were left to 
dry overnight at room temperature.  
3.2.2 Histology and Immunohistochemistry 
Sections were stained with Luxol-fast blue/hematoxylin and eosin (LFB-HE) (Kluver & 
Barrera, 1953), H&E (Mallory, 1938), Bielschowsky silver impregnation (Yamamoto & Hirano, 
1986), and a modified Turnbull staining protocol (Meguro et al., 2007). Immunohistochemistry 
was performed using an Avidin-Biotin technique as detailed in chapter 2, section 2.2.  
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3.2.3 X-ray Fluorescence Imaging 
Rapid scanning microfocused XFI was performed on beamlines 2-3 and 14-3 at the 
Stanford Synchrotron Radiation Lightsource (SSRL). Fifteen μm-thick samples collected on 
plastic coverslips were mounted onto a motorized stage oriented at 45° to the incident beam. 
Beamline 2-3 was used to examine iron (6210 – 6700 eV) with an incident energy of 12.5 keV, a 
spot size of 3 μm x 3 μm and a dwell time of 120 ms/point. Beamline 14-3 was used to image 
sulphur (2260 – 2360 eV) and phosphorous (1960 – 2060 eV) with an incident energy of 4.25 keV, 
a 5 μm x 5 μm spot size and a dwell time of 50ms/point.  
3.2.4 Chemically Selective Imaging 
Chemically selective imaging was carried out on beamline 2-3 at five-micron resolution 
and using a dwell time of 100 ms. Images were collected at incident energies of 7118.5 eV, 7126.5 
eV, and 7132 eV corresponding to Fe-S clusters, ferrous iron, and ferric iron, respectively. 
3.2.5 Fourier-transform Infrared Microspectroscopy 
FTIR imaging was performed on the MidIR beamline at the Canadian Lightsource (CLS) 
using the Hyperion 3000 FTIR imaging system (Bruker Optics, Ettlingen, Germany) that is 
equipped with a liquid nitrogen cooled 64 x 64 Mercury-Cadmium-Telluride (MCT) focal plane 
array (FPA) detector with a 15X magnification. The spectral resolution was set to 4 cm-1 and the 
data were acquired in transmission mode. Each individual element of the array detector sampled 
an area approximately 2.7 x 2.7 μm². Pixel binning (8x8) was applied so that a larger area of the 
sample could be imaged and 128 scans were collected per pixel. The experiments were performed 
at room temperature and data were collected using the Bruker spectrometer software, OPUS. 
Before imaging the sample, a background spectrum was collected from the slide absent of the 
sample. The final absorbance spectra were calculated from the ratio of the background spectra / 
sample spectra. The benefits of using ratios are that it can eliminate the variability from sample 
thickness and also helps to overcome problems arising from spectral pre-processing. 
Infrared images were generated using the ratio of the integrated area of absorption bands 
of interest. The protein infrared images used the integrated area under the amide I region (1700 – 
1600 cm-1): 1660 – 1650 cm-1 for alpha helices and 1635 – 1620 cm-1 for beta sheets. The area of 
3000 – 2800 cm-1 is associated with the C-H stretches of lipids. The lipid oxidation infrared image 
was generated using the ratio of the integrated area of CH2 (2895-2946 cm
-1) and CH3 (2895-3000 
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cm-1). The CH3 absorption band (2958 cm
-1) was normalized to observe the changes in the acyl 
chain upon oxidation. The ester carbonyl band associated with lipid ester was at 1740 cm-1. The 
infrared image of phosphate used the integrated area of anti-symmetric stretches of phosphate at 
1280 – 1200 cm-1.  
3.2.6 Image Analysis 
XFI image analysis was performed using Sam’s Microanalysis Toolkit (SMAK; Open 
Source, Samuel Webb, SSRL, Stanford, CA, USA). All images were normalized to I0 to account 
for variations in incoming beam intensities. XFI data were not quantified in this study. 
All FTIR spectral processing and classifications were carried out using OPUS software 
(Version 7.2, Bruker, Ettingen, Germany), and Cytospec software (Cytospec, version 2.00.01). All 
the spectra were preprocessed and the water vapor contribution was subtracted. In order to 
eliminate any intensity variation caused by changes in the thickness of the tissue, the spectra were 
normalized. Baseline correction was done with software Cytospec by using polynomial fitting.  
3.2.7 Statistical Analysis 
The paired t test was used to assess the differences in markers of oxidative stress between 
the lesions and PPWM. The p-values shown did not account for the SDs. Ignoring the SDs is not 
a concern because they are similar across the subjects. The paired t-test was preferred to a GEE or 
other model-based analysis that may not be reliable with so few subjects. One drawback of the 
paired t-test analysis was that it excluded case 5 who only had demyelinated lesions and no PPWM 
for paired comparison.  
3.3 Results 
3.3.1 Tissue Pathology 
The cohort examined in this study included three male and three female patients, ranging 
from four to seventy-nine years of age. The patients’ clinical data were not available and therefore 
the diagnosis of definite MS could not be fulfilled. Thus, all patients presented here had the 
diagnosis of clinically isolated syndrome (CIS), which is a single neurological episode suggestive 
of MS. However, all six biopsies showed pathological findings consistent with MS: confluent 
demyelinated lesions infiltrated by a sea of myelin-laden macrophages. Perivascular 
demyelination consistent with acute disseminated encephalomyelitis (ADEM), or astrocytic 
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damage, aquaporin-4 (AQP4) loss, granulocyte infiltration, myelin vacuolation and vascular 
fibrosis consistent with neuromyelitis optica (NMO) were not found. Only two of the six cases 
could be immunopatterned because they contained early active lesions. The other four cases 
contained late active lesions.  The markers of oxidative injury in demyelinated lesions and PPWM 
were compared in this study.  
3.3.2 Differential Distribution of Sulphur, Phosphate, And Iron in Demyelinated Lesions and 
Periplaque White Matter 
XFI revealed that sulphur was decreased in demyelinated lesions in all six biopsies (Fig. 
3.1A) when compared to PPWM (Fig. 3.1B). Sulphur was uniformly distributed in demyelinated 
lesions, but in Case 1, increased sulphur was present around blood vessels (Fig. 3.1A, asterisks) 
and co-localized with an area containing a high density of perivascular macrophages (Fig. 3.1G, I, 
K). Haemorrhagic areas contained the most sulphur in the PPWM (Fig. 3.1B, H, J, arrows). 
Phosphorous was lost in the demyelinated lesions in all biopsies (Fig. 3.1C) but not in 
PPWM (Fig. 3.1D). Similar to the distribution of sulfur, higher phosphorous co-localized with 
perivascular macrophages in the demyelinated lesion (Fig. 3.1C, G, I, K, arrows). As opposed to 
sulfur, the haemorrhagic areas contained the lowest phosphorous in the PPWM (Fig. 3.1D, H, J, 
arrows).  
The loss of both sulphur and phosphorous in the demyelinated lesions corresponded to the 
myelin loss, reflected by a loss of PLP immunoreactivity (Fig. 3.1G) and a lack of LFB-HE 
staining (Fig. 3.1I) compared to the PPWM (Fig. 3.1H, J). 
The distribution of iron varied between biopsies. Iron distinctly localized to perivascular 
macrophages (Fig. 3.1E) and hemorrhages in lesions in two cases. Only two cases did not show a 
distinct difference in iron distribution between the demyelinated lesions and PPWM. The identity 
of macrophages was confirmed with CD68 immunohistochemistry (Fig. 3.1K). The iron in PPWM 
most likely corresponded to oligodendrocytes and myelin (Fig. 3.1F). CD68 
immunohistochemistry showed a uniform distribution of microglia in the PPWM (Fig. 3.1L).  
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Figure 3.1 X-ray fluorescence imaging of an MS biopsy reveals loss of sulphur and 
phosphorous in demyelinated lesions, and accumulation of phosphorous and iron in 
perivascular macrophages. Sulphur (A) is lost in demyelinated lesions (XFI) and (B) is 
preserved in periplaque white matter (PPWM) where the highest sulphur concentrations 
correspond to hemorrhages (arrow) (XFI). (C) Phosphorous is lost in the demyelinated 
lesion, but accumulates in macrophages surrounding blood vessels (asterisks) (XFI). (D) 
Phosphorous is evenly distributed throughout the PPWM and lost at hemorrhage sites 
(arrow) (XFI). (E) Iron is lost in demyelinated lesions, but accumulates in perivascular 
macrophages (XFI). (F) Iron in PPWM has a patchy distribution (XFI). (G) Myelin loss is 
confirmed by absence of proteolipid protein immunoreactivity (PLP) while (H) myelin is 
preserved in the PPWM with visible hemorrhages (arrow) (PLP). (I) Luxol-fast 
blue/Hematoxylin & Eosin also shows complete loss of myelin in the lesion (LFB-HE). (J) 
Myelin appears blue in the PPWM and hemorrhages stain dark purple (arrow) (LFB-HE). 
(K) macrophages accumulate perivascularly, they also in the brain parenchyma (CD68). (L) 
Activated microglia are present in the PPWM (CD68). Intensity scale bar applies to all XFI 
images and represents the normalized total Kα fluorescence counts, proportional to total 
chemical element present with blue as lowest and red as highest. Scale bars: A-D) 100 µm; 
E & F) 60 µm; G- L) 1 mm.  
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3.3.3 Ferrihydrite is the Predominant Iron Species in Perivascular Macrophages  
Because there was such a remarkable amount of iron seen in the perivascular macrophages 
in the demyelinated lesion of case 1 (Fig. 3.1E), chemically specific iron imaging was performed 
on this case alone to determine form of iron present macrophages. Interestingly, perivascular 
macrophages in the lesion contained mostly ferrihydrite (Fig. 3.2C). The amounts of iron-sulphur 
clusters (Fig. 3.2A) and ferrous iron (Fig. 3.2B) in the lesion were negligible. Similarly, the 
majority of iron in the PPWM was ferrihydrite (Fig. 3.2F), with very little amounts of iron-sulphur 
clusters (Fig. 3.2D) and ferrous iron (Fig. 3.2E) present. 
Because ferrihydrite is the mineral core of ferritin, all six biopsies were stained 
immunohistochemically for heavy-chain ferritin (HF) and light-chain ferritin (LF). Myelin (Fig. 
3.2G), perivascular macrophages (Fig. 3.2H), astrocytes and nuclei of some oligodendrocytes were 
immunoreactive for HF in the demyelinated lesions. In the PPWM, HF stained myelin and 
oligodendrocytes (Fig. 3.2I).  
Myelin was immunonegative for LH in the lesions (Fig. 3.2J) and PPWM (Fig. 3.2L). In 
the demyelinated lesions macrophages (Fig. 3.2K) and reactive astrocytes were immunoreactive 
for LF, while in the PPWM, LF stained microglia (Fig. 3.2L).  
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Figure 3.2 Chemically specific XFI shows most iron in demyelinated lesions and normal 
appearing white matter is stored as ferrihydrite. Chemically specific XFI shows the absence 
of (A) Fe-S clusters (XFI) and (B) ferrous iron (XFI) in the demyelinated lesion. (C) Most 
iron in the demyelinated lesion is ferrihydrite (XFI). Similarly, (D) iron-sulphur clusters 
(XFI) and (E) ferrous iron (XFI) are mostly absent in the periplaque white matter (PPWM), 
except for small amounts present in hemorrhages (F, arrow). (F) Most iron in the PPWM is 
present as ferrihydrite (XFI). Ferritin immunohistochemistry shows H-ferritin 
immunoreactivity on (G) myelin (HF) and in (H) perivascular macrophages (HF). (I) H-
ferritin in PPWM is localized to oligodendrocytes (arrows). (J and K) Macrophages in the 
demyelinated lesions (LF) and (L) activated microglia in the PPWM (LF) are 
immunoreactive for L-ferritin. Intensity scale bar applies to the all XFI images and represents 
the normalized total Kα fluorescence counts, proportional to total metal present with blue as 
lowest and red as highest. Scale bars: A-F) 100 µm; H & K) 50 µm; I & L) 33.3 µm; G & J) 
200 µm. 
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3.3.4 Lipid Oxidation Precedes Oxidation of Proteins 
Several different areas within the lesion and PPWM were chosen for spectrum collection 
and the spectra shown in figure 3.4A represent an average of all collected spectra. The CH2/CH3 
and CH2/total lipid ratios can be used as indicators of lipid oxidation. Demyelinated lesions had 
lower CH2/CH3 ratio than PPWM (Fig. 3.4A), which was consistent across all biopsies (Fig. 3.5A). 
A reduced CH2/CH3 ratio likely indicates increased lipid oxidation and can be due to lipid acyl 
chain unsaturation occurring during lipid peroxidation. However, oxidation of proteins may lead 
to production of carbonyl groups on amino acid residues that also contribute to the changes seen 
in CH3. Thus, using CH2/total lipid ratios bypasses the use of CH3 confirming the presence of lipid 
oxidation. Quantification of lipid oxidation using the two ratios of CH2/CH3 and CH2/ total lipid 
is listed in Table 3.1.  
There were also changes in the carbonyl ester (C=O) vibration at 1740 cm-1 that was mainly 
associated with the lipid ester. Lipid ester is an important functional group associated with myelin 
and demyelinated lesions had lower lipid ester than PPWM (Fig. 3.4A).  
Protein conformational changes were indicated in the Amide I region (1700-1600 cm-1), 
which mainly arise from C=O stretches from the protein backbone (Miller, Bourassa, & Smith, 
2013). The shift in the position of the Amide I band and the appearance of a shoulder indicated 
altered protein secondary structure within the demyelinated lesion (Fig. 3.4A).  
Further analysis of second-derivative spectra (Fig. 3.4B), to enhance peak deconvolution, 
revealed increased intensity at 1635-1620 cm-1 and decreased intensity at 1660-1650 cm-1. These 
alterations are characteristic of increased beta sheets and decreased alpha-helix protein secondary 
structures in demyelinated lesions (Table 3.1). Increased beta sheets/protein aggregation was 
consistent across all biopsies (Fig. 3.5B).  
There were changes in asymmetric phosphate (P-O) vibration at 1240 cm-1 with lower 
phosphate in demyelinated lesions compared to PPWM (Fig. 3.4A). Lower phosphate in 
demyelinated lesions was observed across all biopsies (Fig. 3.5C and Table 1).  
While infrared imaging suggested a decrease in alpha helices in lesions versus the PPWM 
(Fig. 3.3A and B), this difference was not statistically significant (p=0.13) (Fig. 3.6). There also 
was no difference in the amount of total proteins between the lesions and PPWM (p=0.3) (Fig. 
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3.6). There was a trend for increased beta sheets in demyelinated lesions (p=0.07) compared to 
PPWM (Fig. 3.3C and D), and this increase reached statistical significance when beta sheets were 
normalized to either normal conformed proteins (p=0.03) or total proteins (p=0.05) (Fig. 3.6). 
Total lipids were significantly decreased in demyelinated lesions (p=0.05, Fig. 3.3E) 
compared to PPWM (Fig. 3.3F) and oxidized lipids accumulated in demyelinated lesions (Fig. 
3.3G) versus PPWM (Fig. 3.3H) (CH2/CH3 p=0.04 and CH2/total lipid p=0.02). Notably, not many 
of the lipid-rich perivascular macrophages contained oxidized lipids (Fig. 3.3H).  
There was significant phosphate loss in lesions (p=0.04, Fig. 3.3I) compared to PPWM 
(Fig. 3.3J).  
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Figure 3.3 Infrared imaging of demyelinated lesion of an MS biopsy shows oxidation of 
proteins and lipids. Alpha helices, indicative of normal proteins, are decreased in 
demyelinated lesions (A), but not in periplaque white matter (PPWM) (B). Beta sheets, an 
indicator of proteins with abnormal conformation, are increased in demyelinated lesions (C) 
when compared to PPWM (D). Total lipids are lost in demyelinated lesions (E), but is not in 
the PPWM (F). Perivascular macrophages contain high amounts of lipids (E, arrow). Lipid 
oxidation is more prominent in demyelinated lesion (G) than in the PPWM (H). Phosphate 
is lost in the lesion where it accumulates in perivascular macrophages (I), but is preserved in 
the PPWM (J).  
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Figure 3.4 FTIR analysis shows increase lipid oxidation, accumulation of beta sheets and 
loss of phosphate in demyelinated lesions. The solid (dark grey) and dotted (light grey) lines 
indicate spectra collected from the periplaque white matter (PPWM) and lesions, 
respectively. The lipid spectra from the lesion and PPWM are staggered for better 
visualization of changes in the CH2/CH3 ratio. (A) The spectra show the differences between 
demyelinated lesions and the PPWM in the lipid, protein, and phosphate (P-O) regions. A 
reduction of the CH2/CH3 ratio indicates lipid acyl chain cleavage due to oxidation; a shift 
in the Amide I band indicates changes in protein secondary structure; decreased phosphate 
in demyelinated lesions. (B) The second derivative of the absorbance spectrum of Amide I 
(1700-1600 cm-1) was performed to resolve the changes in alpha and beta protein secondary 
structures. Beta sheets (1628 cm-1) accumulate in demyelinated lesions compared to the 
PPWM.  
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Table 3.1 Integrated intensities of molecular vibration bands of lipid, protein and phosphate.  
 
Cases* 
 
Total 
lipid 
 
Oxidized 
lipid 
CH2/CH3 
 
CH2 / 
Total 
lipid 
 
Total 
protein 
 
 
β-
sheets 
 
 
α-helix 
 
β-
sheets / 
α-helix 
 
β-sheets/ 
Total 
protein 
 
Phosphate 
1-M 
 
11.765 
±0.211 
2.902 
±0.098 
0.685 
±0.065 
24.809 
±1.408 
3.308 
±0.154 
6.124 
±0.245 
0.540 
±0.075 
0.133 
 ±0.021 
0.775  
±0.101 
1-D 6.117 
±0.128 
1.443 
±0.082 
0.537 
±0.041 
24.355 
±1.821 
3.842 
±0.165 
5.337 
±0.331 
0.719 
±0.068 
0.158 
±0.025 
0.390 
±0.085 
2-D 6.402 
±0.154 
1.804 
±0.101 
0.582 
±0.076 
24.975 
±1.654 
3.550 
±0.162 
5.761 
±0.268 
0.616 
±0.056 
0.142 
±0.023 
0.355 
±0.099 
2-M 10.172 
±0.232 
3.011 
±0.121 
0.665 
±0.081 
24.294 
±1.81 
3.458 
±0.173 
5.769 
±0.219 
0.599 
±0.045 
0.143 
±0.019 
0.678 
±0.089 
3-M 11.086 
±0.258 
2.85 
±0.121 
0.658 
±0.074 
24.356 
±1.671 
3.175 
±0.147 
5.837 
±0.276 
0.544 
±0.043 
0.130 
±0.021 
0.680 
±0.097 
3-D 9.513 
±0.215 
2.41 
±0.119 
0.508 
±0.101 
23.943 
±1.862 
3.475 
±0.171 
5.839 
±0.292 
0.595 
±0.049 
0.145 
±0.016 
0.601 
±0.087 
4-M 7.343 
±0.165 
2.29 
±0.088 
0.608 
±0.062 
24.169 
±1.615 
3.390 
±0.132 
5.732 
±0.198 
0.519 
±0.042 
0.140 
±0.023 
0.460 
±0.078 
4-D 7.090 
±0.154 
2.013 
±0.101 
0.59 
±0.058 
22.763 
±1.436 
3.345 
±0.148 
5.367 
±0.210 
0.623 
±0.039 
0.147 
±0.017 
0.423 
±0.067 
5-Da 8.452 
±0.233 
2.275 
±0.109 
0.674 
±0.098 
23.941 
±1.722 
3.500 
±0.155 
5.620 
±0.188 
0.622 
±0.041 
0.146 
±0.022 
0.435 
±0.088 
5-Db 7.465 
±0.198 
2.17 
±0.111 
0.613 
±0.114 
23.665 
±1.587 
3.563 
±0.169 
5.517 
±0.199 
0.646 
±0.055 
0.150 
±0.027 
0.329 
±0.099 
6-D 7.113 
±0.208 
2.454 
±0.089 
0.539 
±0.103 
23.912 
±1.489 
3.403 
±0.179 
5.637 
±0.201 
0.604 
±0.051 
0.142 
±0.019 
0.581 
±0.092 
6-M 8.830 
±0.199 
2.813 
±0.097 
0.616 
±0.118 
24.264 
±1.621 
3.077 
±0.187 
5.871 
±0.216 
0.524 
±0.049 
0.127  
±0.023 
0.741 
±0.084 
Values presented with mean ± standard deviation. M = myelinated; D = demyelinated lesion; Da 
= first demyelinated region; Db= second demyelinated region 
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Figure 3.5 Graphical summary of oxidative damage markers in MS lesions compared to 
PPWM. Estimates with 2SD “error bars” or “precision bars” for myelinated (orange points) 
or demyelinated (blue points) lesions for each case. There is a significant increase in oxidized 
lipids and aggregated proteins, and a significant decrease in phosphate in MS lesions 
compared to the PPWM.  
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3.4 Discussion 
A significant role has been proposed for oxidative injury in the process of demyelination 
and neurodegeneration in MS lesions (Lassmann, 2014a). This study clearly shows that oxidative 
injury of lipids and proteins is present in biopsied MS lesions and increased compared to the 
PPWM. Furthermore, I show that demyelinated lesions exhibit extensive lipid oxidation with 
comparatively low protein oxidation, indicating a possible temporal sequence where the oxidation 
of lipids precedes that of proteins. These findings also agree with previously published studies 
showing that oxidative injury is involved early in the pathogenesis of MS lesions (Haider et al., 
2011).  
Unsaturated fats, abundant in the CNS, are vulnerable to oxidative damage, and lipid 
peroxidation is a marker of oxidized lipids (Barnham, Masters, & Bush, 2004). Lipid peroxidation 
occurs when ROS attack carbon-carbon double bonds in lipids leading to formation of carbonyl 
groups (carbon atoms double bonded to oxygens) and the subsequent breakdown of long CH2 
chains into fragments (Ayala et al., 2014; LeVine & Wetzel, 1998). When the CH2 chains are 
broken, a hydrogen is picked up by the fragments resulting in the creation of CH3. Thus, an increase 
in CH3 and a decrease in CH2 is indicative of oxidized lipids. Oxidative damage in actively 
demyelinating MS lesions has been previously reported through the use of immunohistochemistry 
to detect the oxidative damage markers, 4-HNE and nitrotyrosine, indicative of damage to lipids 
and proteins, respectively. Foamy macrophages and hypertrophic astrocytes in actively 
demyelinating lesions contain high amounts of these oxidative markers. Using FTIR, my study 
confirms that biopsied active MS lesions contain significantly higher levels of oxidized lipids than 
PPWM. However, oxidized lipids do not co-localize with myelin-laden macrophages, but they are 
dispersed throughout the demyelinated lesion, possibly in reactive astrocytes or oligodendrocytes. 
A  more recent study has found oxidized lipids primarily in oligodendrocytes and myelin within 
active MS lesions (Lassmann, 2014a). Oligodendrocytes are more vulnerable to oxidative damage 
compared to other glial cells due to their low levels of antioxidant enzymes, rendering them less 
efficient at responding to oxidative injury (Juurlink, Thorburne, & Hertz, 1998; van Horssen et al., 
2008). Macrophages contain notably high levels of antioxidants (van Horssen et al., 2008) and are 
more resistant to oxidative damage. An in vitro study has shown that ingestion of human myelin 
by macrophages induces the expression of anti-inflammatory molecules characteristic for the M2-
phenotype  (Boven et al., 2006). Another study has found that myelin-laden macrophages in 
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demyelinated lesions express less p22phox and gp91phox, both of which are parts of the NADPH 
oxidase 2 (Nox2) complex (Fischer et al., 2012), and the deletion of gp91phox helps protect the 
animals from getting EAE (Li, Vana, Ribeiro, & Zhang, 2011). Thus, I believe that myelin-laden 
macrophages may serve a protective role in oxidative stress and also are important in resolving 
inflammation in MS lesions.  
Lipid-rich areas have a prominent ester carbonyl band representing lipid esters (Caine et 
al., 2012). In the present study, MS lesions contained less lipid ester than PPWM, most likely due 
to the loss of myelin in the demyelinated lesions. XFI showed loss in sulphur that is likely also a 
reflection of demyelination since the sulphur-containing sulfatides are abundant constituents of 
myelin (Stuber et al., 2014).  
To function normally, proteins need to fold into three-dimensional conformations. Partially 
folded or unfolded polypeptide chains are unstable and can aggregate into insoluble complexes 
(Cooper, 2000). FTIR is sensitive to protein secondary structures (Miller et al., 2013) and can be 
used as a unique fingerprinting tool to determine the relative protein secondary structure content 
or to determine alterations in protein secondary structure. The hydrogen bonding influences 
vibrational frequency and the variation in the polypeptide hydrogen bonding environment that is 
associated with different protein secondary structures is reflected in the position and intensity of 
the amide I band observed in FTIR spectra. I found a shift in the amide I band in demyelinated 
lesions indicating a change in the conformation of proteins. Analysis of the secondary structures 
showed that demyelinated lesions contained less normally folded proteins and significantly more 
aggregated proteins than PPWM. Interestingly normally folded proteins were relatively preserved 
compared to lipids and oxidized lipids in demyelinated lesions. This suggests that there is a 
temporal relationship in which oxidation of lipids precedes oxidation of proteins in MS lesion 
formation.  
Protein oxidation can occur indirectly in a secondary protein carbonylation reaction, in 
which the end products of lipid peroxidation, such as 4-HNE, modify proteins and their function 
(Mirzaei & Regnier, 2008; Suzuki, Carini, & Butterfield, 2010). Protein oxidation leads to non-
specific protein to protein interactions creating aggregates that compromise cell viability (Mirzaei 
& Regnier, 2008). Carbonylation is a type of protein oxidation that is often used as a marker of 
oxidative stress (Suzuki et al., 2010). Aggregated proteins can also result from primary protein 
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carbonylation reactions, which is direct oxidative attack resulting in the addition of carbonyl 
groups on amino acids such as proline, arginine, lysine, and threonine (Crichton, Dexter, & Ward, 
2011; Fritz & Petersen, 2011). The aggregated proteins found in MS lesions may form similarly 
to amyloid plaques observed in Alzheimer’s disease. Amyloid plaques are found in diseased 
tissues and have high β-sheet structure (Barnham et al., 2004). The present study showed an 
accumulation of β-sheets in demyelinated lesions compared to the PPWM suggesting the presence 
of protein oxidation and possible shared mechanism of damage between MS and some 
neurodegenerative disorders.  
A few demyelinated lesions in this study were infiltrated with myelin-laden macrophages 
containing iron. It has been suggested that iron is liberated when the oligodendrocytes and myelin 
are destroyed in MS and taken up by microglia and macrophages (Hametner et al., 2013). In the 
one case where iron was chemically speciated, ferrihydrite, the mineral core of the iron storage 
protein ferritin, was the predominant iron species present in macrophages. Macrophages can alter 
expressions of proteins involved in iron metabolism to sequester iron, rendering it unavailable for 
pathways or pathogens that depend on iron (Gammella et al., 2014). This suggests that 
macrophages may play a protective role and attenuate tissue damage by sequestering free iron in 
demyelinated lesions, and argues against iron-caused oxidative damage in the earliest MS disease 
stages. 
The reduced amount of phosphate and phosphorous found in the demyelinated lesions is 
likely due to demyelination and the subsequent loss of phospholipids. Cellular membranes are 
particularly vulnerable to oxidative damage because of the high concentrations of unsaturated fatty 
acids (Mukwevho et al., 2014). Active MS lesions express high levels of glutaminase (Carvalho 
et al., 2014), which is activated by inorganic phosphate (Bellocchio et al., 1998). Macrophages 
ingesting myelin and phosphatidylserine, a myelin phospholipid, have decreased nitric monoxide 
(NO) secretion that may slow disease progression (Bogie et al., 2013).  
There is increasing evidence that oxidative stress plays a significant role in the 
pathogenesis of early MS, and it has become increasingly important to elucidate the mechanisms 
and characteristics of oxidative injury in human MS tissues. The oxidative damage in early MS 
does not seem to be driven by iron accumulation, and this again argues against the use of iron 
chelators in the treatment of early MS. However, the important role of oxidative injury of myelin 
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and oligodendrocytes plays in the earliest disease phases may open new therapeutic avenues for 
using antioxidants in the treatment of at least a subset of patients with RRMS. 
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Chapter 4 General Conclusions and Future Directions 
Multiple sclerosis (MS) is the most common neurological disease of young adults for which 
there is no cure, but there are treatments available that can offer some degree of control over the 
inflammatory process reducing the frequency and severity of attacks (MS International Federation, 
2015). Research suggests that relapsing-remitting MS benefits from early therapeutic interventions 
and this requires prompt and accurate diagnosis at the earliest stages of the disease (Katz Sand, 
2015). It is becoming clear that the pathogenesis of MS is heterogeneous and more complex than 
previously thought. The presence of pathological heterogeneity between MS patients suggests that 
the mechanism of tissue injury and the mechanism of demyelination is distinctly different in 
different patient subgroups (Lucchinetti et al., 2000). None of the currently available therapeutics 
are effective for all MS patients and the reason behind this may be the heterogeneity of disease. It 
has been shown that different immunopatterns respond differently to various treatments: 
immunopattern II, but not immunopattern III, patients respond to plasmapheresis for treatment of 
steroid unresponsive MS relapses (Keegan et al., 2005). Thus, it is important to develop non-
invasive methods to distinguish between the different immunopatterns in living patients. To 
accomplish this, it is crucial to identify reliable biomarkers for use in, for example, MRI. In my 
thesis, I used a multimodal approach with X-ray fluorescence imaging (XFI), Fourier-transform 
infrared spectroscopy (FTIR), and routine histology and immunohistochemistry to identify such 
potential MS biomarkers.  
The content and distribution of iron within early active MS lesions is a promising 
biomarker that may be able to distinguish between immunopatterns. XFI is a novel tool that has 
not been previously used in a systematic way to study human MS brain tissues. While the first 
study has determined that there is a differential iron content and distribution between 
immunopattern II and III active lesions, additional studies are required to validate my findings in 
vivo using MRI. Several MRI techniques have been proposed to be sensitive to iron (Bagnato et 
al., 2011; Mehta et al., 2013; Zheng et al., 2013) and MRI is already used for studies of iron 
deposition in brains of living patients (Ropele et al., 2011). Therefore, these MRI modalities will 
have to be validated by XFI (Hopp et al., 2010; Zheng et al., 2013) and may be adapted for the 
identification of MS immunopatterns. 
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Immunopattern heterogeneity is characteristic for white matter lesions of early relapsing 
disease. The presence of early active MS lesions is a prerequisite for immunopattern classification, 
and this becomes problematic for patients with lesions that have evolved to a different 
demyelinating stage, for example late active or chronic lesions. Heterogeneous immunopatterns 
may ultimately converge into a uniform homogeneous pattern that contributes to MS progression 
in the absence of ongoing relapses. While immunopathological immunopatterns are no longer 
distinguishable in chronic MS, the iron signature that differentiates immunopattern II from 
immunopattern III MS may still be present. Future studies using late active or inactive lesions from 
patients with known immunopatterns will have to establish whether the iron accumulation that 
characterizes MS immunopatterns is still present past the early active lesion stage and can still 
differentiate between patients with immunopattern II and immunopattern III MS during the chronic 
disease phase. 
Oxidative stress promotes demyelination and neurodegeneration in early MS (Lassmann, 
2014b) and oxidized DNA, lipids, and protein are often found in active MS lesions (van Horssen 
et al., 2008). It has been proposed that oxidative damage in MS is driven by iron accumulation, 
but I show here that in early MS, demyelinated lesions are devoid of iron, a finding inconsistent 
with iron-driven oxidative tissue damage. Using FTIR imaging and XFI, I propose a list of 
potential biomarkers for early lesions: increased oxidized lipids and aggregated proteins, and lower 
amounts of iron, sulfur, phosphorus and phosphate. Future studies will have to establish if these 
markers can be identified in vivo using MRI, MR spectroscopy and/or other imaging modalities. 
Future studies will also have to establish if these oxidative biomarkers, in addition to iron, correlate 
with various immunopatterns. The identification of such in vivo biomarkers for early MS lesions 
and immunopatterns will allow the immunophenotyping of MS patients without the need of 
biopsy, an invasive and dangerous procedure. Furthermore, it will allow the stratification of MS 
patients and will have potentially significant therapeutic implications, as individualized 
therapeutic approaches to treat the early stages of the disease may need to be considered. 
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